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1.1 BAX/BCL-2 HETERODIMERIZATION IN APOPTOSIS OF THE
HEMATOPOIETIC CELL LINE 32DCL3(G) DETECTED BY
LASER CONFOCAL MICROSCOPY, R. Gradini*, I. Silvestri, P. Sale, L. Giuliani, M.
Realacci, A. Gradilone, P. Gazzaniga, 0. Gandini, C. Santangelo, G. Naso and A.M.
Aglian6, Dpt. ofExp. Medicine and Pathology, "La Sapienza" University, Rome, Italy.
The modulation of transcriptional expression of bax, proapoptotic, and bcl-2,
antiapoptotic genes, is an early event in the p53 mediated programmed cell death.
Oltvai and coworkers related this phenomenon to Bax/Bcl-2 heterodimerization
(1). Recently, Knudson et al. proposed the possibility that bax and bcl-2 genes are
able to regulate the apoptosis independently (2).
Our experimental model, a non-tumorigenic interleukine-3 (IL-3) dependent
murine hematopoietic cell line 32D C13(G), which undergoes terminal
differentiation into granulocytes when exposed to granulocyte colony stimulating
factor (G-CSF), offers a convenient system to study the expression of genes
involved in apoptosis. In a previous work, we showed that apoptosis induced by
IL-3 deprivation from the culture medium is substained by p53, which in turn
modulates the bcl-2 and bax expression (3).
In the present work we studied the. heterodimerization of Bax and Bcl-2 by
Laser Confocal Microscopy. The IL-3 treated cells showed a low colocalization
index of Bax and Bcl-2 (heterodimerization), as detected by immunofluorescence.
The colocalization index was much higher in cells deprived of IL-3 after 5 hours.
The colocalization index was very high also in the presence of G-CSF in the
culture medium (after 16 hours).
Our study shows that Bax/Bcl-2 heterodimerization is an early event, related to
IL-3 withdrawal from the culture medium, in the apoptotic pathway of 32D C13(G)
cells.
1. Oltvai ZN, Milliman CL, Korsmeyer SJ. Cell 74: 609-611, 1993.
2. Knudson CM and Korsmeyer SJ. Nature Gewnetics 16:358-363, 1997.
3. Aglianb AM, Naso G, Silvestri I, Gradilone A, Vercillo R, Napolitano M,
Gazzaniga p, Gandini 0, Realacci M, Santangelo C, Saccani G, Manzari V, Frati
L. Intern.J. Oncol. 11:1271-1277, 1997.
1.3 VITAMIN D ANALOGUES POTENTIATE TNFa AND
CERAMIDE INDUCED APOPTOSIS IN HUMAN BREAST
CANCER CELLS, G. Pirianov, S.Y. James and K.W. Colston, Dept. of Cellular and
Molecular Sciences, St George's Hospital Medical School, London SW17 ORE
Previous studies have demonstrated that synthetic vitamin D analogues induce
apoptosis in cultured breast cancer cells and cause regression of experimental rat
mammary tumours. Mechanisms by which vitamin D analogues promote apoptosis
could involve suppression of cell survival signals and/or induction of genes that
stimulate apoptosis. In the present study we have examined whether vitamin D
analogues may potentiate responsiveness of breast cancer cells to known mediators of
apoptosis. TNFa is a potent cytokine which demonstrates anti-tumour activity both in
vivo and in vitro and induces apoptosis in a variety of tumour cell lines. We have
assessed the effects of two synthetic vitamin D analogues, EB 1089 and CB 1093, in
addition to the native hormone, 1,25(OH)2D3, on the cytotoxic action of TNFa on
MCF-7, T47D and Hs578T human breast cancer cells. In MCF-7 cells, pretreatment
with the vitamin D analogues (0.2 5OnM) was found to substantially potentiate the
cytotoxic effects of rhTNFa (0.2 20ng/ml) assessed by neutral red staining, with
CB1093 being the most potent. MCF-7 cells pretreated for 65h with 2OnM CB1093
showed 75% cytotoxicity with TNFa (20ng/ml for 22h) compared to 30% in control
cultures. CB 1093 also potentiated cytotoxic effects of TNFa in T47D cells. Hs578T
cells were resistant to TNFa-induced apoptosis in the presence or absence of vitamin D
compounds. Mechanisms involved in the potentiation of TNFa-induced apoptosis are
unknown but vitamin D derivatives may promote recognition of the TNFa stimulus
or promote a common apoptotic pathway. Generation of ceramide through hydrolysis
of sphingomyelin appears to play a role in TNFa induced apoptosis. Since
1,25(OH)2D3 has been reported to activate the sphingomyelin cycle in several
leukaemic cell lines, we have assessed interactions between the vitamin D analogues
and ceramide on breast cancer cell proliferation, cell viability and apoptosis (quantitated
by MTS dye-reduction and DNA fragmentation assays). MCF-7, T47D and Hs578T
breast cancer cells were pretreated with CB 1093 (5OnM for 48h) and exposed to C2
ceramide (0.5 20jM for 24h). In control cultures, loss of cell viability was observed
with C2 concentrations >5gtM. However, pretreatment with CB1093 increased
responsiveness to C2 such that significant cytotoxicity was detected with 0.5, 1.0 and
2.5tM C2 in MCF-7, T47D and Hs578T cells respectively. CB 1093 was also able to
increase the level of ceramide-induced intranucleosomal DNA fragmentation in all
breast cancer cells. These findings suggest that ceramide might be involved in a
common pathway in TNFa and vitamin D-mediated apoptosis.
1.2 DIETHYMALEATE, A GLUTATHIONE DEPLETING
AGENT, INDUCES APOPTOSIS IN ADENOCARCINOMA PROSTATE
CANCER CELL LINES R. N.T. Coffey, RW.G. Watson, E. Murphy,
J.M.Fitzpatrick, Dept. of Surgery, MaterMisericordiae Hospital, Eccles St. Dublin 7.
Prostate cancer is the second most prevalent non-cutaneous cancer among men in
Ireland representing 10.6% of all cancer. The adult male prostate is chronically
dependent upon a continuous supply of androgen in order to maintain a steady state
equilibrium of cell proliferation and prostatic cell death. Androgen ablation, widely
used in prostate cancer treatment, induces apoptosis of the prostate cancer cells. A
certain fraction of the prostate cancer cells are capable of surviving androgea
withdrawal. These androgen independent cells pose a problem in terms of current
antiproliferative therapeutic treatments. Clearly such cells arc capable of avoiding or
inhibiting the cellular mechanism that activates cell death.
Gluthathione (GSH) depletion is an earlystage ofapoptosis andchemical depletion of
such an endogenous antioxidant is associated with the induction of apoptosis in
human neutrophils. (Watson et al., Surgery 120: 150-158,19961
AIMS: Diethybnaleate (DEM), a known glutathione depleting agent, was
investigated in relation to its ability to induce apoptosis in both androgen sensitive
(LNCaP) andinsensitive (PC-3) human adenocarcinomaprostate cancercell lines.
METHODS: LNCaPandPC-3 cells were treatedwith differentconcentrations ofDEM
(25-250 uM). Apoptosis was assessed four days post-treatment by propidium iodide
DNA staining and confirmed by Annexin V and DNA gel electrophoresis. GSH
depletion was measuredby the DTNB colourimetric assay.
Table: % Apoptosis GSH depletion
(Propidium Iodide Incorporation (nM/WO cells) _F B E FroP. B
CON. 25uM 100uM 250uM 120 u1\4 CON. 250uM
I.N('aP 20.63 __ 51.93 80.3 62.02 34.7 12.5
± 5.8 ±10.54* ± 1.2* ± 4.4* ± 1.7 ±3.75*
PC-3 3.34 5.05 23.2 37.25 38.37 69.6 27.45
± 1.4 ±f 0.4 ± 1.5* ±4.8* ± 2.6* . 2.5 i 1.55*
Results = Mean ± SD, * p<0.05 vs. CON. (Students t-test)
RESULTS: DEM which inhibited cellular proliferation was also shown to induce
apoptosis in a dose dependent manner in both the androgen sensitive and insensitive
cancer cell lines (Table). Associated with apoptotic induction was a depletion in the
level of intracellular glutathione. The ability of glutathione depletion to induce
apoptosis in androgen sensitive and insensitive cells may demonstrate a potential
clinical role for this drugin the treatment ofprostate cancer.
1.4 CONTROL OF NORMAL AND MALIGNANT HUMAN
UROTHELIAL CELL DEATH AND SURVIVAL BY THE TNF
SUPERFAMILY.
U. Bugajska, J. Southgate & L.K. Trejdosiewicz. ICRF Cancer Medicine Research
Unit, St James's University Hospital, Leeds LS9 7TF, UK.
Members of the Tumour Necrosis Factor (TNF) receptor family are
crucial in controlling lymphoid cell survival and elimination. However, the
significance of their expression by normal versus malignantly-transformed
epithelial cells is poorly understood.
We have studied a human uroepithelial cell system. Transitional cell
carcinoma (TCC) cell lines (EJ, T24, 253J, RT112, VM-CUB-3, VM-CUB-1,
COLO-232, KK47, RT4, HT1197) were used and compared with the normal
human urothelial (NHU) cells (Southgate et al, Lab Invest 1994; 71: 583).
CD40 ligation was studied using soluble trimeric CD40L and by co-culture
with CD40L-transfected fibroblasts (3T3CD40L) or control transfectants
(3T3neo). The effects of TNFa and ligation of Fas (CD95, Apo-1) receptor
were also investigated. Cell death was analysed by flow cytometry using
Annexin V and propidium iodide and confirmed by the 'JAM" test of DNA
fragmentation.
All 14 NHU cell lines tested but only 4/10 TCC cell lines expressed
CD40. The CD40+ TCC cell lines underwent extensive apoptosis after co-
culture with 3T3CD40L, but not 3T3neo. Soluble CD40L was growth
inhibitory but did not induce apoptosis in TCC cells and ligation ofCD40 had
no effect on NHU cells. TNFa was growth inhibitory to NHU and some, but
not all, TCC cells. NHU from some donors did not undergo TNFa-mediated
apoptosis, whereas others were moderately susceptible. The well- and
moderately-differentiated RT4 and RT112 TCC cell lines, respectively,
underwent extensive apoptosis, increased even further by inhibition of
protein synthesis with cyclohexamide (CHX). By contrast, anaplastic EJ
cells were resistant to TNFa-mediated apoptosis, and only moderately
sensitive with CHX. NHU cells were susceptible to Fas-mediated apoptosis,
as were RT4 and RT112. EJ cells were completely resistant, unless in the
presence of CHX.
Thus, these data demonstrate a differential sensitivity to CD40-
ligation in normal versus tumour cells. Some carcinomas may escape
immune-mediated destruction by either failure to express CD40 or by
avoiding apoptosis following ligation of TNF/Fas receptors by an active
mechanism involving protein synthesis.8 Oral Presentations
S1.FEGFR BLOCKADE ON HN5 CELLS BY TK INHIBITOR OR
ANTIBODY INDUCES TERMINAL DIFFERENTIATION AND
APOPTOSIS. H. Modjtahedi 1, K. Affleck2, C.Stubberfield2 andC.Deani. IThe Institute
ofCancer Research, Sutton.2Glaxo/Wellcome Medicines Research Centre, Stevenage, UK.
Human squamous cell carcinomas frequently overexpress the epidermal growth
factor receptor (EGFR) and this is often associated with poor prognosis in patients
with these cancers. The high level ofexpression ofthe EGFR provide an important
target for therapy and we and others have shown that monoclonal antibodies
(mAbs) which block the activation of the receptor by the EGF family of ligands
inhibit the growth of EGFR overexpressing tumours in vitro and induce the
regression of established tumours grown as xenografts in athymic mice (e.g.
Modjtahedi H, Komurasaki T, Toyoda H and Dean C (1998) Int. J. Cancer 75, 310:
Modjtahedi H, Eccles S, Sandle J, Box G, Titley J, and Dean C (1994) Cancer
Research 54, 1695). Inhibitors of the tyrosine kinase associated with the EGFR
have also been shown to block receptor activation and prevent tumour cell
proliferation. Using the EGFR-overexpressing head and neck carcinoma cell line
HN5, we have compared the biological consequences of treatment with an inhibitor
of EGFR tyrosine kinase (PD153035) with anti-EGFR monoclonal antibodies
(mAbs) ICR63 or ICR80. We found that both the anti-EGFR mAbs and the TK-
inhibitor produce similar biological changes namely, they inhibit the EGF and TGF
a-induced tyrosine phosphorylation of the receptor and the growth in culture of
HN5 cells. At concentrations above 100nM, the TK inhibitor prevented the growth
in culture of HN5 cells completely with an IC50 of 40nM. With the anti-EGFR
mAbs, growth of HN5 cells was inhibited completely at concentrations above 4nM.
More importantly, we found that like the anti-EGFR mAbs treatment with the TK-
inhibitor directs HN5 cells to undergo terminal differentiation as monitored by the
expression of cytokeratin 10. Furthermore, this was accompanied by apoptosis as
determined by 7-Amino Actinomycin D staining (7-AAD). We conclude that EGFR
blockade by anti-EGFR mAbs or TK-inhibitor influences the growth in culture of
EGFR overexpressing tumnours by directing terminal differentiation and inducing
apoptosis. It remains to be seen whether the combined treatment with anti-EGFR
mAbs and TK inhibitors offer therapeutic advantage over individual treatment or
the use ofconventional therapies.
1.7
A LOW-RISK DIET PROTECT AGAINST
COLON CANCER BY UP-REGULATING APOPTOSIS
Richard J. Hambly*', Morag Cunninghame', Philip Brown', Philip J. Rijken2 and Ian R.
Rowland'. 'BIBRA International, Carshalton, Surrey, SM5 4DS, UK; 2Unilever Research
Laboratorium, Vlaardingen, The Netherlands.
The aim of this research was to evaluate whether diet played a role in the regulation of
apoptosis, since the induction of programmed cell death may represent a possible
mechanism ofprotection against cancer ofthe colon
30 Sprague-Dawley rats were randomly allocated to receive diets containing either high-risk
(HR) or low-risk (LR) factors for colon cancer for 3 weeks (Hambly, R.J. et al. 1997. Nutr.
Cancer 27: 250). One day before post mortem, 1,2-dimethylhydrazine (DM1) in saline was
administered orally at 0, 5, 10, 20 and 25 mg kg-' body weight to 3 animals per group. At
post mortem the colon was removed, formalin fixed, and 1cm regions of the proximal, mid
and distal colon were embedded in paraffin wax. Sections (5pm) were rehydrated, protein
digested by a 15 minute digestion with 25gsg ml' proteinase K at 20°C, and endogenous
peroxidase removed by treatment with 2% H202 for 5 minutes at 20°C. An ApopTag plus kit
(Appligene-Oncor, France) was used to stain apoptotic bodies in crypts. Adjacent sections
were stained with haematoxylin and eosin (H&E) to confirm the incidence of apoptotic cells
by conventional histology. The number of whole crypts per slide and the numbers of
apoptotic bodies in transverse sections of whole crypts were counted. Data was analysed
after logl0 transformation using an ANOVA model based on a factorial design with repeated
measures.
Oral dosing with the carcinogen DMH induced a significant dose-dependent increase
(p<0.001) in apoptosis in the colon. Carcinogen-induced apoptosis was significantly
increased in the colonic crypts of animals receiving a LR diet compared with those receiving
a HR diet (p<0.001). Analysis of the colon by region showed significantly less apoptosis
occurred in the proximal colon compared with the distal or mid colon regions (p<0.001).
There was also a strong trend (p-0.053) to indicate that the rate of apoptosis in the mid
region was greater than in the distal region ofthe colon. Statistical analysis highlighted two
other significant effects: Firstly, there was a significant region by diet interaction (p<0.05),
indicating that the low-risk diet increased the rate of apoptosis by a greater amount in the
distal and mid regions of the colon than the proximal colon. Secondly, for both diets, there
was a significant (p<O.OO1) region by dose interaction, indicating that the higher the dose of
DM1 the greater the difference between the proximal region, which had the lowest rate of
apoptosis, and the other two regions.
Our results suggest that diet-induced up-regulation of apoptosis represents a mechanism of
protection against the early stages ofcarcinogenesis in the colon.
1.6 REGULATION OF TUMOR CELL SURVIVAL BY THE
IGF-I RECEPTOR C-TERMINUS. Rosemary O'Connor*', Mariana
Resnicoff2 Renato Baserga2 Eileen Dalton', Maureen MeDonagh' Department
of Biochemistry, University College, Cork, Ireland' and Kimmel Cancer
Center, Thomas Jefferson University, Philadelphia, USA
The insulin-like growth factor I receptor (IGF-IR) activated by its
ligands IGF-I or IGF-II, mediates suppression of apoptosis, which is critical
for tumourigenesis and for the maintenance of tumour cells. There is a very
strong association between the levels of circulating IGF-I/IGF-II and IGF-IR
expression with tumors of the lung, breast, and prostate. Circulating IGF-II
levels were recently shown to be a better indicator of prostate cancer than
prostate specific antigen. Therefore, the IGF-IR is a very rational target for
pharmacological agents that would inhibit the survival oftumor cells.
The C-terminus ofthe IGF-IR has a negative impact on the ability of
the receptor to suppress apoptosis, and seems to constitute a regulatory domain
for the receptor (O'Connor et al., Mol. Cell Biol. 17: 427-435, 1997) A critical
role for the C-terminus in regulating IGF-IR-mediated tumor cell survival was
confirmed by studying this domain expressed as protein derivatives in tumor
cells. The membrane-targeted C-terminal derivative, MyCF, was found to
induce apoptosis when transiently transfected into MCF-7 breast carcinoma
cells, and it sensitized the cells to U.V irradiation. This could be reversed by
specific point mutations, suggesting that the pro-apoptotic effect was due to a
dominant-negative effect caused by sequestering molecules that normally
interact with the C-terminus ofendogenous IGF-IR (Liu et al., Cancer Res. 58:
570-576, 1998).
In order to further study the activity of the C-tenninal derivatives they
were stably transfected into MCF-7 cells and ovarian carcinoma cells CaOV3.
MyCF inhibited tumorigenesis in nude mice and induced apoptosis in vivo.
This could be blocked by over-expression of Bcl-2. MyCF did not alter IGF-
IR-mediated activation of P-43 kinase and AKT kinase, both of which are
implicated in suppression of apoptosis by the IGF-I receptor. This suggests
that the C-terminal derivatives induce apoptosis by blocking apathway distinct
from the P13 kinase/AKT pathway, or alternatively by activating a pro-
apoptotic pathway.
Determining how the C-terminal derivatives suppress IGF-IR-
mediated cell survival should lead to possibilities for blocking this pathway in
tumors, and also elucidate the regulatory mechanisms ofthe IGF-I receptor.
1.8 MYCOBACTERIAL DNA INDUCES APOPTOSIS IN
TUMOUR CELLS, M.C. Filion*', R. O'Shea2, J.K. Collins2
and N.C. Phillips', 'Facultd de Pharmacie, Universitd de Montreal, Qc.,
Canada, H3C 3J7, 2Dept. of Microbiology, University College Cork,
Ireland.
Live mycobacteria or mycobacterial preparations possess potent anti-
tumour activity. This anti-tumoural activity has been ascribed to cell wall
components or to immunostimulatory proteins. A mycobacterial cell wall
complex (MCC) derived from the non-pathogenic Mycobacterium phlei (M.
phlel) has been shown to have anti-tumour activity. In analysing the
composition of MCC we found that it contains approximately 5% DNA in
the form of short oligonucleotides (approximately 100 base-pairs). We
have therefore evaluated whether DNA extracted from MCC or from M.
phlei directly induces apoptosis in tumour cells. The induction of apoptosis
was determined by a) inhibition of tumour cell proliferation, b)
nucleosome-sized DNA fragmentation, c) the release of soluble nuclear
mitotic apparatus protein (NuMA) and d) the presence of hypodiploid
peaks in flow cytometric analysis of cellular DNA.
We have found that DNA extracted from either MCC or from M. phlei
directly induces apoptosis (incubation time 48-72 hours) in a wide range
of human and murine tumour cell lines in the absence of immune effector
cells. The tumour cells tested were: human monocytic THP-1 leukemia,
human pro-monocytic HL-60 leukemia, murine monocytic RAW 264.7
leukemia, human Jurkat T lymphoblast, murine B-16 melanoma, human
colon SW260 adenocarcinoma, human oesophageal squamous OC2
carcinoma, human transitional bladder HT-1 197 and HT-1 376 carcinoma.
The induction of apoptosis appears to be independent of tumour cell type
and of escape mechanisms such as Fas-ligand and drug resistance, since
all cells tested enter apoptosis after contact with M. ph/ei-derived DNA.
DNAse treatment of MCC, DNA extracted from MCC or from M. phlei
significantly inhibits the induction of apoptosis. We further demonstrate
that the induction of apoptosis does not appear to be related per se to the
methylation state of putative CpG motifs or to the molecular weight of the
DNA.
The induction of apoptosis by mycobacterial DNA may help to explain
the therapeutic activity of a number of mycobacterial preparations in the
treatment of cancer.
Acknowledgement. We wish to thank Bioniche Inc., London, Ontario,
Canada, for kind gift of MCC used in this study.Oral Presentations 9
TOPOISOMERASE II IS A TARGET FOR ANTHRACYCLINE-
MEDIATED ACTIVATION OF NFKB
Marion P. Boland*, Gillian J. Callan and Luke A.J. O'Neill.
Department of Biochemistry, Trinity College, Dublin 2.
The anthracycline antibiotics, daunorubicin and mitoxantrone, can
activate the transcription factor, NFKB, and induce K1B-dependent gene
expression in HL60 cells. Reactive oxygen species generated by
endogenous cellular processes have been implicated in this activation, and
not ceramide, although its levels are raised in cells in response to these
drugs [1]. In continuing studies, we have investigated the role of
topoisomerase H (topo 11) enzymes, a major target for these drugs, in
mediating mitoxantrone-induced NFicB activation. Topo II enzymes modulate
DNA topology by introducing transient double-strand breaks into the DNA
backbone, allowing passage of an intact helix through the broken DNA. Topo
Il-targeted drugs stabilize this reaction intermediate giving rise to protein
associated strand breaks. Mammalian cells possess an alpha and a beta
isoform, both of which may be important targets for anthracyclines. We have
found that a reduction in the level of the beta isoform of topo 11 profoundly
effects the ability of mitoxantrone to induce both NFKB activation and
apoptosis in non-mdr HL60-MX cells, compared with the the parental cell line
(HL60-P), where a dose-responsive activation was observed. The absence
of the beta isoform was confirmed by immunoblot analysis. Significantly, both
cell lines were equally response to apoptotic induction and NFKB activation
by agonists which do not act via topo H enzymes, suggesting that pathways
leading to these events are intact in these cells. In further studies, Adr-1 cells
(non-mdr phenotype) displaying a 3-4 fold hypersensitivity to mitoxantrone,
were responsive to NFKB activation whereas the parental cell line (CHO) was
only weakly responsive at the highest doses employed. Apoptotic induction
paralleled these observations, and topo 11 alpha levels were confirmed to be
elevated in Adr-1 cells. The cellular level of topoisomerases may dictate the
therapeutic efficacy of anthracyclines drugs. These enzymes may also be
novel candidates which regulate the activation of the transcription factor,
NFKB, in response to such agents which damage DNA. As NFKB activation
may be involved in apoptosis, this effect may be an important aspect of the
cellular responses to the anthracyclines.
[1] Boland, M.P., Foster, S.J. and O'Neill, L.A. (1997) J.Biol.Chem., 12952-12960.
anthracyclines NFKB topoisomerase 11 apoptosis
2.3 A PHASE ONE PHARMACOKINETIC
STUDY OF CGS27023A, A MATRIX
METALLOPROTEINASE INHIBITOR. N.C. Levittl*, F.Eskens2, D.J.Propperl, A.L.Harrisl, L.Denis2, T.S.Ganesanl, R.A.Mather3, L.McKinleyl, A.Planting2, D.C.Talbotl, V.Van Beurden2,
M.Van der Burg2, S. Wilneri and J. Verweij2. t: ICRF Unit, Churchill Hospital, Oxford OX3 7AR. U.K. 2:
Rotterdam Cancer Institute and University Hospital, Ronterdam, Netherlands. 3: Novartis, Switzerland.
CGS27023A is an orally administered, broad spectrum matrix
metalloproteinase inhibitor with antitumour activity in various animal
models. In this phase one study 36 patients, (median age 56 years,
range 32 to 74, 12 female, 24 male, median PS = 0), with advanced
solid tumours, ( colorectal 10, mesothelioma 6, melanoma 4, other
16) have been entered to date, at five dose levels (150mg bd - 600mg
tds) for a total of 340 patient weeks (median 7 weeks, range <1 to 45
per patient). Two main toxicities were observed. Five patients
developed a widespread, self limiting maculopapular rash after 1 week
of treatment, 3 of whom discontinued therapy. Rash was not
observed at doses < 300mg bd. Nine patients developed mild to
moderate myalgia/arthralgia, one of whom stopped treatment. One
patient also developed palmar nodules, which resolved after stopping
the drug. Six patients had mild nausea (CTC < grade 1).
Musculoskeletal events and nausea were not dose related. There was
no myelotoxicity. Dose limiting toxicity was not observed.
Pharmacokinetics showed CGS27023A was rapidly absorbed and
eliminated with minimal accumulation after 28 days continuous
dosing. Plasma concentrations >10 x IC 50 for the target enzymes
(including collagenase-MMPl, gelatinase-MMP9 and stromelysin 1-
MMP3) were observed at all dose levels, with Cmax within 1 hour of
dosing. Plasma levels > 5 x IC 50 lasted for 10.6 and 20.0 hours, per
24 hours, at 300mg bd and 600mg tds, respectively. Seven patients
had stable disease and remained on treatment for > 12 weeks (2 each
on 150mg bd, 300mg bd, and 600mg bd and 1 on 400mg tds). There
were no tumour regressions. In conclusion CGS27023A appears well
tolerated at a doses < 300mg bd with biologically relevant plasma
levels. At higher doses the only major toxicity was rash, observed in
5/22patients.
2.2 Validation of pharmacologically-guided dosing of
carboplatin in paediatric patients. Thomas HD, Boddy AV,
Pearson ADJ, Pinkerton CR, Lewis I, Stevens M, Imeson J, Hobson R, and Newell
DR. CRU, University ofNewcastle upon Tyne, for New Agents Group, UKCCSG.
Pharmacologically-guided dosing of carboplatin based on renal function (RF) is
common practice in adults (Calvert JCO, 7:1748 (1986)). A similar approach has
been proposed to optimise dosing of carboplatin in paediatric patients (Newell
JCO, 11: 2314 (1993)). This study investigated the accuracy and precision ofthis
method of dosing compared to conventional dosing based on surface-area (SA).
Thirty nine patients, aged 0.3-16.2 (median 3.4) years, were randomised to receive
carboplatin dosed to a target AUC using either RF or SA, crossing over to the
alternative dosing method on the next course. GFR ranged from 27-114ml/min/m
The target AUC was defined as 1.325mg/ml.min per I00mg/M2 of carboplatin
based on the median clearance. The interval between courses varied from 20 to 83
days.
Dosing using either RF or SA resulted in an AUC that, on average, was not
different to the target. There was no difference between the methods in the
average AUC as a % of target. However, the variation about the target AUC was
less for RF (standard deviation (SD)=17%, interquartile range (IQR)=25%) than
for SA (SD=25%, IQR=36%) (p=0.02). Also, the proportion of courses falling
within 20% of the target was larger for RF than for SA (74 vs 49%, p=0.05). By
direct comparison, AUC using SA dosing differed from target by 22%, compared
with 13% for RF based dosing (p=0.001).
Thus, in this prospective, randomised cross-over study, RF based dosing results in
more reproducible and reliable AUC than dosing ba..cd on SA. The proportion of
courses outside an acceptable range with SA based dosing suggests that this is of
clinical significance.
2.4 PHASE 1/11 DOSE ESCALATING STUDY OF GEMCITABINE AND PACLITAXEL IN NON-
SMALL CELL LUNG CANCER (NSCLC): PRELIMINARY REPORT.
KJ O'Byrne*', S Beare', F Shields', R Sharma', K Jeyapalan2, WP Steward',
'University Department of Oncology, Leicester Royal Infirmary, and
2Department ofRadiology, Glenfield General Hospital, Leicester, UK.
Gemcitabine (Gem) and paclitaxel (Taxol) each have response rates
in the region of20% in the treatment ofNSCLC. Either agent combined with
a platinum gives response and 1 year survival rates of 40 - 50%. Low dose
weekly Taxol, infused over 1 hour, has equivalent anti-tumour activity to
standard Taxol in relapsed ovarian cancer but reduced toxicity. In a phase
1/11 study we evaluated escalating doses of Gem and Taxol given weekly on
days 1, 8 and 15 of 28 day cycles in chemotherapy naive NSCLC patients
(pts). Taxol was given over 1 hour followed by Gem over 30 minutes. Two
cohorts of 3 pts, 5 men and 1 woman: age range 54 - 76 years, were treated.
Cohort 1 - Taxol 40 mg/m2 & Gem 800 mg/m2; cohort 2 - Taxol 40 mg/m2 &
Gem 1,000 mg/M2. Dexamethasone 8 mg, chlorpheniramine 10 mg and
ranitidine 50mg were given intravenously as premedication 30 minutes before
chemotherapy. Dexamethasone 8 mg bid po was continued for 24 hours with
metaclopramide 10 -20 mg tid po pm for nausea. Pneumonitis was seen after
4 cycles in 1 pt in cohort 1 and after 2 cycles in 1 pt in cohort 2.
Investigations, including bronchial washings in 1 and a lung biopsy in the
other, showed no evidence of an infective aetiology. The pneumonitis
responded to high dose prednisolone. Pulmonary infiltrates also developed in
the 2 other pts in cohort 1. An empyema was diagnosed in 1 case and
progressive disease in the other. Treatment was discontinued in the remaining
2 pts in cohort 2 after 2 cycles due progressive disease in 1 and an
uncontrolled, tumour related, recurrent pleural effusion in the other. The
combination was otherwise well tolerated without significant alopecia, nausea
or vomiting, neuropathy, arthralgia or haematological complications. Three
pts had partial responses to therapy. Pneumonitis, a recognised complication
of Gem and also reported for Taxol, appears increased by using the agents in
the schedule described. Given the encouraging anti-tumour activity and
absence of other side-effects we will focus on understanding the pathogenesis
of, and on preventing the pneumonitis induced by weekly Gem and Taxol.10 Oral Presentatons
2.5 TREATMENT OF ADVANCD REFRACTORY BREAST
CANCER WITH DOCETAXEL ALTERNATING WVITH EPIRUBICIN AND
CYCLOPHOSPHAMIDE (EC) +G-CSF.
G.WiDnnaKrT G.V.Korek, KiHaider. MIRaderer. J.Valencak. W.Kasny.
E.Bareck, D.Depisch, E.Kovats and W.Scheithauer. Deptof InLMed-L
Univrsity.of Vienna, and Depts-of Surgen-. Wiener Neustadt and Baden General
Hospitals. Austria
Fourtv consecutive patients with advanced breast cancer failiig pallatve 1st-
line chemotherapy (without antacclines) were entered in this tial. 34 of
them are currently evalualuble for response and toxicit asses . Fourteen
were pre-. 19 were postmenopausal. and 1 was male. Their median age was
53 (41-72) years. and the median WHO r a status 1 (0-2).
Predomiant umor ste were visceral in 29. and bone in 3 and soft-tisse im
2 patients. Prior 1st-line c tpy consisted of CMF (n=9).
vinorelbine/5-FU/leucovorm' (n=13) or vinorelbine/gemcitabine (n=12).
Salvage treafnct consisted of 3-ekly courses ofdocetaxel 100 mg/m2 iv
altern ng with epirubicmI 100 mg/m2 + cvclophosphainide 800 mg/m2 + G-
CSF Smc/kg/day given subcutan shl for 5 days followig chemotherapo.
After a neian of6 (2-6) t n courses. 19/34 (56%) evahlable patients
had objective tmor responses, imcluding 5 CRs (15%); 8 additonal patients
(24%) had stable disease, and 7 progessive disease. The median time to
response was only 2.0 (1-5) months. the median duration ofboth response and
survival have not been reached yet. Dose-limiting hematologic side effects
(WHO grade 4) occurred in 10 patients. and were complicated by septiceniia
in 3. Severe nonatlogic side effects (WHO 3) were noted in 3 patients
and consisted ofstmatits in 2 andneurotoxicity in 1. Alopecia occured in all
patients and was complete in 20 (59%/o). Other freqntly encountered. dto
generalh mild adverse reactions were nausea/vomiting (47%b) and diarrh
(24%). We concle that docetaxel altrnaing ith EC/G-CSF is a venr
active regimen for the treatment ofadvanced breast cancer refiactory to (non-
anthracycline cotainin) st-line chemotherapy
2.7 RRADIOIIIMMONOGULDED SURGERY tRIGS E OFCOLORECTAL
2.7 CANCER ATIH SINGLECHAIN FvANTIBODY TO CEA. G.MI
Boxer'. A. \ia\er. D. O'Malle\. E. Tsiompanou. M. C. Winslet. A. A. A Lewis. A. P.
Dhillon. A. J W'. Hilson and R. H. J Beeent- CRC Targeting & Imaoing Group. Dept. of
Clinical. Oncoloes. Ro\al Free and L'CL Medical Schools. London NA 'PF.
In RIGS radiolabelled anti-tumour antibod\ is gsven intravenously to patients before
operation to resect cancer Peroperatiselv the surgeon uses a hand-held gamma-detectine
probe to locate tumour deposits in which radiolabelled antibody has localised The probe is
extremel\ sensitise and mak-es it possible to locate tumour deposits which are not detectable
b\ the consentional means of inspection or palpation Cons entionalls RIGS has been
performed usine a whole IgG anitbods but these clear slowly from the bloodstream half
life '4-2 hrs) so that it is usualls neccessarv to wait 4 weeks or more after injection before
surger\ is perbormed which is too lona for manv clinical situations VAe hase de%eloped a
ceneticall\-eneineered single .hain F\ antibod\ iNMFE-2) directed acainst
carcinoembrsonic antigen iCEA, with a much lower molecular weight than IaG 21' % 150
kD Clearance from the circulation is more rapid than IgG and gises the prospect ot
perlormine surgern at much earlier times, with better discnrmination between tumour and
normal tissues XXe hase produced MIFE-23 in a form suitable for clinical use. labelled it with
-'iodine Io and conducted a RIGS trial 1 mg of I"1-antibods 90-28-5 MBq was gisen.
'4. 4. -' or 96 hours betore operation to 20 patients hasing surger for primars or
recurrent colorectal cancer At surgerv counts were compared oser areas ot tumour and
adjacent normal tissue and were correlated with histologx from the resected specimens to
confirm the presence or absence of cancer Blood samples were taken from pateints at
intersals following injection 2: minutes-96 hourso Fresh samples of tumour and normal
tissue from resected specimens Aere assa\ed for radioactisitt usine a eamma counter
Pharmacia. U K a and expressed as counts per minute/gram Tumour to normal tissue ratios
were calculated and expressed as mean for each group Slices of formalin-fixed tumour and
normal tissues i0 '-0 cm thick; were exposed to phosphor storage plates for up to 33weeks
and the plates were scanned w-ith a phosphorimager 400A Mlolecular Dynamics. U K. to
cenerate a dieital map of the distnbution of radioactiit\x These distributions were
correlated with photoeraphic images to determine the specificit\ of radiolabelled antibods
localisation in tumour For the 20 patients no adserse esents were obsersed Plasma
clearance ot \FE2'- was biphasic with an a half life ot Is minutes and a 5 half life of 2'6
hours Tumour to normal tissue ratios were 1 1 24 hrsn 22'-l 48 hrs). 44 41 2 7 hrsi and
42' 1 196 hrsm Takine all time points and all cancer lesions togeether RIGS was 88'% accurate
in identix_in tumour deposits (true positise +9 c true negative 9c%1 No false positise
cases were recorded. Phosphor images demonstrated a close correlation between tumour site
and lcocalisation of radiolabelled antibodv. Ve conclude that RIGS with %IFE-2 sinele chain
Fx antibods is safe and effectise in locating tumour deposits and 12 or 96 hours is the
optimal atier injection time tor surgen. Including more patients at the optimal time points
will establish the utilits of RIGS in identifline occult tumour which can be resected or for
demonstrating extensis e disease for which major surgery is not appropriate.
2.6 POTENnAL FOR DOSE ESCALATION OF CHART IN NON
2NON SMALL CELL LUNG CANCER(NSCLC):
COMPARISON OF TWO STRATEGIES FOR LOCO-REGIONAL CONTROL.
C. McGibney*t O. Holmberg2. B McClean2, C. Williams3, P.Suttonl, J. ArmStrong'.
Departs. ofRadiation Oncologyt, Physics2 Radiology3. St Luke's Hospital, Dublin.
Purse: To compare the dose escalation possible for continuous, hyperfraction-
ated. accelerated radiotherapy (CHART) for NSCLC using two altenative
treatment strategies for loco-regional control: (1)Clinical strategy of elimination of
electise nodal irradiation (EN!) alone or (2) Utilization of3-D, conformal radiation
therapy(3DCRT) also with the elimination elective nodal irradiation (i.e. 3D-EN1
plans).
Methods: Standard CHART therapy plans,which include ENI, were generated
using consentional 2D technology for 18 patients with NSCLC, stages Ib-IIb.
Further 2D plans were generated but with the elinination ofENI from the treat-
ment portals thus forming 2D-ENI plans. Both sets were reconstructed in three
dinensions using the patients planning CT studies and subsequently compared
with alternative 3D-EMN plans. generated de novo.
Baseline dose delivery to the primary tumour and to organs at risk was compared
between the reconstructed 2D CHART, 2D-ENI and the 3D-ENI plans. The
potential for escalation ofdose beyond the 54Gy,the standard dose ofCHART,
using the 2D-ENI and the 3D-EMNI plans, was also assessed.
Results: Target coserage was significantly reduced in the 2D CHART and the
2D-EN1 plans when compared to the 3D-EMNI plans, p=0.0001 and p=0.003,
respectis ely The target volume receiving the recommended (ICRU-50) 95%0 of
the dose prescribed (NV95) was reduced in the 2D CHART and 20-EN!I plans
by 140o and 1?°o. respectively . p=0.0001. Maximum point dose to the spinal
cord was reduced to an average of l9Gy in the 3D-EMN plans from an average
of40Gy and 39.7 Gy in the 2D CHART and 2D-EN! plans,respectvely.
p=0.OOOl and p=0.0005. The mean and median dose to the oesophagus and
heart were also significantly reduced in the 3D-EN! plans.
Dose escalation ,w-ith the recommended target coverage retained, was possible
m 10 18 ofpatients using the 3D-EIN! strategy but in only 2, 18 patients
usmng a strategy of elimination ofEN! alone. Dose escalation varied from 40 to
1350owith a median escalation of22% above the standard dose ofCHART. The
degree ofescalation was significantly influenced by the tumour site & N stage.
ANCOVA.p=0.008
Conclusions: 3DCRT is essential for optimum target coverage and facilitates
dose escalation in more than halfthe patients with NSCLC. A clinical policy
of elimination ofelective nodal irradiation alone is not sufficient for either
target cosverage or for dose escalation
2.8 TAMOXIFE ISANTI-ANGIOGENIC L'n C i AND
ATTIEUATES VEG-NMEDATED ANGIOGENESIS uzn *Tw
WrnlOUT ADVERSE IFECIS ONWOUNDHEA ING
DA McNamara*'. J Harmey'. JH Wang'. D Donosan'. E Kay:. TN Walsh' DJBouchier-
Hayes' RCSI Departments of Surgery' and Pathology:. Beaumont Hospital. Dublin
Angiogenesis is essential to tumour growth. We have previously shown
that surgery results in a permissive environment for angiogenesis,
mediated in part by vascular endothelial growth factor (VEGF), and
may therefore paradoxically increase micrometastatic growth. We have
previously demonstrated that tamoxifen reduces serum VEGF in cancer
patients. We hypothesise that tamoxifen inhibits VEGF-mediated
angiogenesis. Our aim was to evaluate the effect of tamoxifen on
angiogenesis and to assess whether its pen-operative use has detrimental
effects on wound healing.
Human microvessel endothelial cells (HMEC) and human umbilical
vein (HUVEC) endothelial cells were cultured in vitro and treated with
tamoxifen in DMSO (100 ng/mi - 2.5jg/ml) or DMSO alone.
Endothelial cell proliferation at 24 and 48 hours was quantified using
5-bromo-2'-deoxyufidine labelling. HMEC, but not HUVEC,
proliferation was attenuated by tamoxifen in vitro at a dose of 2.5 gg/ml
when compared to controls (p=0.001). Adult male Sprague-Dawley rats
were pre-treated with po tamoxifen or placebo for 3 days and then
injected with VEGF-impregnated Matrigel. Tamoxifen or placebo was
continued for 5 further days. Microvessel density within the gel was
quantified. Mean microvessel count in tamoxifen-treated VEGF gels
was decreased when compared to controls (52.6 per high powered field
(hpf) vs 63.3 per hpf, p< 0.05). Endothelial cell migration in vivo was
significantly reduced by tamoxifen therapy (p<0.05). Laparotomy and
small bowel anastomosis were performed on animals pre-treated with
tamoxifen or placebo for 3 days. Therapy was continued up to 10 days
post-operatively. There was no difference in macroscopic indices of
wound healing between the two groups.
In summary, tamoxifen is anti-angiogenic in vitro and in vivo by
reducing VEGF-mediated angiogenesis. T'his effect does not appear to
impair wound healing in the perioperative period. Further evaluation is
warranted to assess the potential role of neoadjuvant tamoxifen in
dormancy therapy of micrometastases in the pen-operative period.Oral Presentations 11
3.1 FUNCTIONAL EVIDENCE OF NOVEL TUMOUR
SUPPRESSOR GENES FOR CUTANEOUS MALIGNANT
MELANOMA. C. N. Parris*, J. D. Harris and R. F. Newbold. Human Cancer
Genetics Unit, Dept. Biology and Biochemistry, Brunel University, Cleveland Road,
Uxbridge, Middx. UB8 3PH.
The incidence of skin cancer is rising faster than any other human
malignancy with some 40,000 new cases each year. About 4,000 are the most
aggressive form, Cutaneous Malignant Melanoma (CM) which are responsible
for 90% ofdeaths due to skin cancer (J. K. Rivers; The Lancet 347: p803, 1996).
Cytogenetic analyses have identified non-random interstitial chromosome
(chr.) deletions (Loss of Heterozygosity: LOH) associated with the development
of CMM. Most prevalent are deletions of chr. 9p21 involving the tumour
suppressor gene CDKN2 (p16) (M. Serrano et al.; Nature 366: p704, 1993).
However, deletion ofchrs. ip, 6q, 10q and 1 lq are common events in melanoma
development. Evidence suggests that these regions contain critical TSGs central
to CMM development. Moreover, while p16 is a well documented TSG for CMM
and other tumours, it often remains intact and LOH occurs elsewhere on chr.
9p2i suggesting the presence of a further TSG on chr. 9p.
In this study, we have used a panel of human chrs. maintained as somatic
cell hybrids in mouse A9 cells. Each human chr. is tagged with a retroviral vector
expressing a HygromycinR-Thymidine kinase fusion gene allowing forward and
reverse selection (A. P. Cuthbert et al.; Cytogenet. Cell Genet. 71: p68, 1995).
We have introduced additional normal human chrs. 1, 6, 9 (Apl6/pI9) and 10
into the human melanoma cell line UACC-903, by Microcell-Mediated
Chromosome Transfer (MMCT). Tumour suppression by the additional chrs. was
determined by cloning efficiency of UACC-903 cells in soft agar (a highly
reliable test for in vivo tumourigenicity). Our results have demonstrated
suppression of the malignant phenotype with chrs. 1, 6 and 10. In addition,
transfer of chr. 9 containing a micro-deletion that inactivates p16 and p19 still
causes suppression, indicating the presence of an additional TSG on this chr..
Transfer of chrs. 5, 8, 15 and 9 (Ap arm) failed to suppress the melanoma cell
line, as expecteddue to the absence ofknown melanoma TSGs.
Reversion ofthe hybrid melanoma cell lines by selection in Ganciclovir to
remove the introduced chr. caused a reversion to the malignant phenotype
(D. A. Trott etal.; Mol. Carcinogenesis 12: p213, 1994).
In order to substantiate these findings, we are currently performing in vivo
tumour studies in nude mice to demonstrate the tumour suppressive action of
chrs. 1, 6, 9 (Apl6/pl9) and 10 for CMM.
3.3-IDENTIFICATION BY DIFFERENTIAL DISPLAY OF
NOVEL GENES EXPRESSED IN BREAST CANCER, R. H. Kao*1, R
Poulsom2, A. H. Hanby3, G. Francial and I. R. Hartl, lRichard
Dimbleby Dept. of Cancer Research/ICRF Lab., St. Thomas' Hospital,
London SEI 7EH, 2Histopathology Unit, ICRF, London WC2A 3PX.
3ICRF Clinical Oncology, Guy's Hospital, London SE1 9RT
In order to explore the in vivo changes in gene expression associated
with breast tumour development, we have applied the rt-PCR-
differential display technique to normal breast compared with a c-
erbB-2 negative, grade 3 invasive ductal carcinoma from a single
patient. Tumour and normal tissue were microdissected from
consecutive frozen sections, mRNA was prepared and subjected to rt-
PCR-differential display. By using 3 anchor primers and 30 arbitrary
primers, 21 differentially expressed cDNA fragments were obtained
in repeat procedures; 11 exhibiting enhanced expression in tumour
material and 10 in normal material. These 21 bands were cloned and
sequenced and 13 of these cDNA sequences were found to be novel
according to GeneBank searches. One of these fragments, 1 2at2,
expressed more highly in the tumour tissue was used as a probe in i n
situ hybridization analyses. In 6 individual breast cancer cases,
including the original patient material from which it was derived;
12at2 was found to be expressed preferentially in invasive cancer
cells relative to stromal, vascular endothelial, inflammatory and
normal mammary glandular cells in which it was not expressed. One
case of ductal carcinoma in situ also expressed 12at2. RT-PCR of ZR75
cells confirmed that 1 2at2 is expressed by this mammary tumour cell
line and efforts are underway to isolate the full-length cDNA b y
screening a ZR75 cDNA library. These results show that the rt-PCR-
differential display technique can be applied to breast cancer
material to identify genes whose expression might be implicated i n
breast cancer progression.
3.2 THE INKL1XE: GR3W FECmRToLY 1 RECIPICR PC
AS A NML CNOE IN AYL ISIS. A
AlLiscn, E Gant, GWilm, K tley, M M atee, CS alt'trde & EK
Habib, Dqrtmrrt f airgery, wetern (meral Hautal, BRirbzgh EH4
This study was designed to examine the role of the insulin-like growth
factor type 1 receptor in human colon carcinogenesis. IGF-1 receptor
expression was determined at the protein and mRNA levels in aberrant
crypts, adenomas and adenocarcinomas from gross resected specimens
and this was compared to adjacent normal epithelium.
Immunocytochemistry has shown upregulation of cytoplasmic-membrane
IGF-1R expression in aberrant crypts (5/5), adenomatous polyps (34(34)
and adenocarcinomas (24/27) in comparison to adjacent normal epithelial
cells for all specimens. The immunolocalization of IGF-1 R was
especially pronounced in the tumoural cell cytoplasm in comparison to the
benign epithelial cytoplasm. There was no correlation between the level
of IGF-1R expression and tumour stage. However, receptor upregulation
was a feature of malignant transformation rather than epithelial cell
proliferation where the authors found lower levels of expression in basal
proliferative crypts and hyperplastic polyps (5/5). The validity of the
result was supported by tissue positive and negative controls, reagent
negative controls (where the antibody was peptide-absorbed with a
purified receptor protein sequence) and Westem blotting where there was
complete molecular weight specificity for a+p subunits at 220kD in
tumoural and normal tissue. Northern blotting for IGF-1 R mRNA
employing specific probes showed a similar difference between colonic
cancers and normal epithelium.
These results show for the first time that IGF-1R upregulation is an
important finding in the colonic polyp-cancer sequence and could be
implicated in the mechanism ofmalignant transformation.
3.4 CLONAL ANALYSIS OF BREAST DCIS USING
DIFFERENTIAL METHYLATION OF HUMARA.
P.Costello*', A.H. McCann'. E.Moore', Thomas Gorey2, and P.A. Dervan.
'Dept. of Pathology and2Surgery. Mater Hospital and University College Dublin, Ireland.
Females inherit a maternal and paternal X chromosome, one ofwhich is
randomly inactivated in each cell by DNA methylation. HUMARA
(Human androgen receptor gene Xq12) is heterozygous in 90% of
individuals and is methylated on the inactive X chromosome. After
treatment with a methylation sensitive enzyme (Ilha 1), only HUMARA
on the inactive X chromosome remains intact as methylation protects it
from digestion. Iftumour cells derive from one cell (clonal theory), the
same X chromosome will be inactivated and only one allele can be PCR
amplified following digestion (monoclonal pattern). Normal tissue on
average contains a mixture ofcells with either X chromosome inactivated
resulting in the availability ofboth alleles for PCR amplification
(polyclonal). The aim ofthis study was to assess clonality in different
grades ofductal carcinoma in situ ofbreast by investigating the
methylation status ofHUMARA (Xq12).
Following microdissection ofDCIS and normal ductal tissue from
paraffin embedded samples, and PCR amplification with nested HUMARA
primers, heterozygous samples were identified (n=l 1). These were Hhal
digested, PCR amplified and electrophoresed. Monoclonality was found
in 7/7 high grade and 2/2 intermediate grade. A polyclonal profile was
found in 2/2 low grade tumours. In addition, monoclonal patches of
normal ductal tissue were identified and microsatellite instability was
found in 2 samples. In conclusion, it appears that high and intermediate
grades DCIS are monclonal, while analysis ofmore low grade samples is
required to establish whether they are polyclonal.12 Oral Presentations
3.5 BRCA1 AND BRCA2 MUTATION SCREENING IN BREAST
CANCER FAMILIES. C.M. Phelan*', J.M. Lancaster2, C.
Gumbs2. P. delos Rios3, J. Abrahamson3, E. Warner, N.A. Parrey1, P.A. Futreai2, S.A.
Narod3.tDept. of Pathology, U.C.D., Ireland. 2Dept. ofSurgery, Duke Univ. Medical
Centre, Durham, NC, USA..3 Womens College Hospital, Toronto, Ontario, Canada.
The BRCA1 and BRCA2 genes are inherited breast cancer genes. We are
currently screening a panel of233 breast (and other) cancer families to
determine the proportion ofbreast cancer families attributable to these
genes. The screening methods include SSCA ofthe coding regions
including exon/intron boundaries, P'IT ofthe large exons (exon 11 in
BRCA1 and exons 10, 11, and 27 in BRCA2) and ASO's for the
Ashkenazi BRCAI mutations. So far,, 44 mutations have been found, 16
in BRCA1 and 28 in BRCA2. Moreover, 73/233 families are negative for
BRCA1. Ofthe remaining 144 families, 106 have been screened by P'T
ofexon 11 but SSCA ofthe entire coding region has yet to be done. In
addition, 176/233 families are negative for BRCA2 mutations as
determined by combined SSCA and PTT, while a furither 21 families have
been screened by PTT only. All ofthe families are being screened for
both genes.
There are a wide variety ofother cancers present in these families. In the
38 families with male breast cancer, 0 BRCA1 and 8 BRCA2 mutations
were observed. Inthe 45 families with ovarian cancer, 7-BRCA1 and 7
BRCA2 mutations have been seen so far, however, a greater number of
families have been screened for BRCA2 mutations than for BRCA1. In he
13 families with pancreatic cancer, 1 BRCA1 and 4 BRCA2 mutations
were observed. Twenty-three families revealed cases ofbilateral breast
cancer, 1 BRCA1 and 2 BRCA2 mutations were found in families with
this feature. In summary, male breast cancer and pancreatic cancer appear
to be indicative ofBRCA2. The occurrence ofbilateral cases ofbreast
cancer does not appear to be wholly indicative of an inherited component,
however, not all the families have been screened in both genes, so this
conclusion is preliminary.
3.7 THE VALUE OF RAPID FUNCTIONAL ASSAYS OF
GERMLINE P53 STATUS IN LFS AND LFL FAMILIES. RS
Camplejohn', R Gilchrist', N Sodha2, ME Lomax', PM Duddy', DM
Barnes3 and RA Eeles2. 'Richard Dimbleby Dept. Cancer Res.,
UMDS, St Thomas' Hospital, London SEI 7EH; 2The Cancer Genetics
Team, Institute of Cancer Research and Royal Marsden Hospital
Trust, Fulham Road, London SW3 6JJ and 3ICRF Clinical Oncology
Unit, Guy's Hospital, London SEl 9RT.
We have tested two rapid assays of p53 function, namely the apoptotic
assay and the yeast-based FASAY as means of detecting germline p53
mutations in members of Li-Fraumeni and Li-Fraumeni like families.
The first assay, the apoptotic assay was developed in our laboratory
and measures the ability of p53 protein to direct DNA damaged cells
into apoptosis following irradiation with 4Gy. The second test, the
FASAY, is a yeast based assay which measures the ability of TP53
protein to transactivate a target gene. Results of the functional assays
have been compared with direct sequencing or, in some cases, SSCP
on material from 50 normal individuals and 22 members of Li-
Fraumeni (LFS) or Li-Fraumeni like (LFL) families. The results show
good agreement between the two functional assays and between them
and sequencing/SSCP. All assays detected mutations in cells from 6
of the LFS/LFL family members. 16 LFULFS family members were
not gene carriers. Thus, no false positives or negatives were seen with
either functional assay although the apoptotic assay gave one
borderline result for an individual without a p53 mutation. As an
initial screen the apoptotic assay is not only rapid but cheap and very
simple to perform. It would be expected to detect any germline defect
that leads to loss of p53 function. The apoptotic assay could be ideal
as a means of pre-screening large numbers of samples and identifying
those which require further investigation. The FASAY detects
mutations in exons 4-10, is rapid and it distinguishes between
functionally important and silent mutations.
3.6 MUTATION ANALYSIS OF VON HIPPEL-LINDAU (VHL)
TUMOUR SUPPRESSOR-ASSOCIATED PROTEINS,CUL-2
AND VBP-1, IN RENAL CELL CARCINOMA (RCC). S.C.Clifford', K.
Hewson', S. Walsh', A. Brinke2, P.M. Green2, F. Gianelli2, A. Pause3, C.
Eng4 and E.R. Maher'. 'Division of Medical & Molecular Genetics,
Department of Paediatrics and Child Health, University of Birmingham, UK,
2Division of Medical & Molecular Genetics, United Medical and Dental
Schools, Guy's Hospital, London, UK, 3Cell Biology & Metabolism Branch,
NIH, Bethesda, MD, USA, 4Dana Farber Cancer Institute, Boston, USA.
Inactivation of the von Hippel-Lindau tumour suppressor gene (VHL, TSG) is
the most commonly detected genetic alteration in the most common form of
kidney cancer (clear cell RCC (CC-RCC)). We have identified somatic VHL
gene mutations in approximately 50% of CC-RCC and a further 15% of
tumours have VHL gene hypermethylation. However the absence of VHL
alterations in a significant proportion of CC-RCC suggests the presence of
alternative genetic mechanisms for CC-RCC development. Mutations in
pVHL interacting proteins such as CUL-2 and VBP-1 could be functionally
equivalent to VHL inactivation and so suggest CUL-2 and VBP-1 as
candidate RCC genes. To test this hypothesis we have mapped and
determined the genomic structure of CUL-2 and performed mutation analysis
on both genes. CUL-2 is a member of the cullins multigene family implicated
in growth control in C.elegans, and VBP-1 maps to Xq21 and encodes a
protein of unknown function. The CUL-2 gene was mapped to human
chromosome 10p11.1 by FISH analysis, and a polymorphic marker from
10p11.1 (D10S176) showed LOH in -10% of CC-RCC. To establish the
CUL-2 genomic structure we have isolated a series of overlapping BAC and
P1 clones by library screening. Direct DNA sequencing of these clones has
to date identified 12 exons and their flanking intronic sequences
(representing 69% of the full cDNA sequence). Mutational screening of the
full-length cDNA sequence of each gene (by SSCP and direct DNA
sequencing) is currently underway in a panel of 100 paired RCC and normal
tissue DNA samples of known VHL TSG status to determine the roles of
CUL-2 and VBP-1 in RCC pathogenesis, and the completed work will be
presented.
3.8 COLORECTAL TUMOURS IN THE FOLLOW-UP OF
ASYMPTOMATIC HIGH-RISK INDIVIDUALS IN
FAMILIES WITH HEREDITARY NONPOLYPOSIS COLORECTALCANCER
(HNPCC). M.Ponz de Leon*', G.Della Casa2, A.Percesepel, P.Benattil, R.Fante3,
C.Di Gregorio4, and L.Roncuccil. 'Dipartimento di Medicina Interna, Universita
di Modena; 2Divisione di Medicina Interna, Ospedale S.Agostino, Modena;
3Servizio di Anatomia Patologica, Ospedale di Mantova, 4Servizio di Anatomia
Patologica, Ospedale di Carpi (Modena).
In Hereditary nonpolyposis colorectal cancer (HNPCC) a close
surveillance is usually proposed to high-risk family members with the objective of
reducing cancer incidence and mortality. We identified 31 families with HNPCC
and contacted a total of 223 first-degree relatives of affected individuals for
counseling. Purposes of the present study were: A) to evaluate overall compliance
among screened individuals and B) to assess the frequency and histologic features
of neoplasms detected at endoscopy. Ofthe 390 subjects traced as "at risk" in the
pedigree, 223 could be interviewed and colonoscopy strongly recommended: the
subjects were re-evaluated at regular intervals. The 86 individuals who agreed to
undergo endoscopic investigations were matched to controls ofthe same age and
sex; these patients required endoscopy owing to minor rectal bleeding, constipation
or abdominal discomfort. Results: Overall compliance was rather poor (86
patients, i.e., 38.6% of the interviewed and only 22.0% of the first-degree
relatives). One or more colorectal lesions were found in 35 out of 86 (40.7%)
family members and in 15 (17.4%, P < 0.01) controls. Among cases, 29 adenomas
in 20 individuals were detected as opposed to 11 (in 9 subjects) in controls (P <
0.05). In asymptomatic family members, adenomas were significantly larger (9.1 ±
5 vs. 5.8% ± 3.7 mm, P < 0.01) and more frequently associated with a
tubulovillous pattern and a high degree of dysplasia. Five carcinomas were
detected among cases (four of which located between the cecum and the splenic
flexure), but only one in controls. Conclusions: Genetic counseling can be carried
out only in part ofhigh-risk individuals in HNPCC families, since the majority of
them cannot be reached or refuse to collaborate. The frequency of newly detected
lesions and their possible aggressive behaviours render colonoscopy at regular
intervals of time (1-2 years) highly recommended in these asymptomatic
individuals at increased risk ofcancer on a genetic basis.Oral Presentations 13
4.1 BREAST CANCER CELL LINES EXPRESS SPECIFIC
BINDING SITES FOR pLR, A NOVEL ANTI-PROLIFERATIVE PEPTIDE
DERIVED FROM FROG SKIN VENOM M.Boyer, H.W.van den Berg, C.Shaw*,
M.Lynch and P.Johnston. Depts. Oncology and Medicine*, The Queen's University of
Belfast
Drugs derived from natural products play an important role in the treatment ofdisease,
including cancer. However, until recently large scale, systematic and rational drug
discovery has not been undertaken. We have initiated studies of the anti-proliferative
properties of natural peptides from a number of sources including those contained in
the dermal venom offrogs.
We have previously shown that pLR, an 18 amino acid peptide, shows potent anti-
proliferative effects towards a number of breast cancer cell lines. The most sensitive
lines studied were an estrogen independent variant of the ZR-75-1 line (ZR-PR-LT)
and a tamoxifen resistant variant of MCF-7, LY2. We have extended these studies to
demonstrate anti-proliferative effects of pLR towards an ovarian carcinoma cell line
PEO4.
We have successfully radio-iodinated pLR and used the product in radioligand binding
assays. Cells in monolayer were exposed to a range of concentrations of 125-I pLR
(10.12 - 6 x 10"M) in the presence and absence of an excess of unlabelled pLR to
account for non-specific binding. All cell lines examined expressed specific binding
sites for pLR. Specific binding of 125-I pLR to ZR-75-1 cells, a tamoxifen resistant
variant ZR-75-9al and an estrogen independent variant ZR-PR-LT was non-saturable
over the concentration range studied, precluding estimates of maximal binding
capacity or receptor affinity. Differences in the level of specific binding between cell
lines were observed, with the highest level of binding being shown by the ZR-PR-LT
line, reflecting its greater sensitivity to the anti-proliferative effects of the peptide. In
preliminary experiments, saturable binding of 125-I pLR to MCF-7 and LY2 cells has
been shown. Binding sites have a high affinity for pLR (Kd 0.8 - 1.4 x 10-"M) and
LY2 cells express a higher number of receptor sites per cell (740) than MCF-7 cell
(450).
We conclude that human breast cancer cell lines in vitro express specific binding sites
for the novel anti-proliferative peptide pLR and that ZR-75-1 cells and variants appear
to express receptors with a lower affinity and/or greater capacity than MCF-7 or LY2
cells. Furthermore, the cell lines most sensitive to the anti-proliferative effects ofpLR
(ZR-PR-LT and LY2) appear to express higher numbers ofreceptors than their parent
lines.
4.3 THE EFFECT OF INSULIN-LIKE GROWTH FACTOR-I ON
THE PROLIFERATION OF HUMAN BREAST CANCER CELLS IN VITRO AND
ON THE SECRETION OF INSULIN-LIKE GROWTH FACTOR BINDING
PROTEIN-2 P.Maxwell* and H.W.van den Berg Dept. Oncology, The Queen's
University of Belfast
The insulin-like growth factor (IGF) system of growth factors, receptors and binding
proteins plays an important role in breast cancer cell proliferation. We have
previously shown that development of anti-estrogen resistance and estrogen
independence in human breast cancer cells in vitro is associated with changes in both
the expression of receptors for IGF-I and the pattern of secretion of IGF binding
proteins (IGFBP's). In particular, we have demonstrated that tamoxifen resistance
and estrogen independence is associated with a reduction in the level of secretion of
IGFBP-2. We have also shown that growth stimulation of MCF-7 cells by estradiol is
accompanied by a reduction in secretion of IFGBP-2 whilst inhibition of cell
proliferation by estradiol in tamoxifen resistant or oestrogen independent breast
cancer cell lines is associated with an increase in IGFBP-2 secretion, suggesting a
growth inhibitory role for this IGF binding protein.
In this study we have investigated the effect of IGF-I on cell proliferation and
secretion of IGFBP-2 in a defined serum-free medium (SFM). Secretion of IGFBP-2
was significantly reduced in the oestrogen receptor (ER) positive cell lines, MCF-7
and ZR-75-1 (p<0.05). IGFBP-2 secretion was also significantly reduced by IGF-I in
the tamoxifen resistant variant of MCF-7 (LY2) and in the estrogen independent
variant of ZR-75-1 (ZR-PR-LT). This reduction in IGFBP-2 was accompanied by
increased proliferation in SFM. IGF-I (5-SOng/ml) stimulated proliferation ofZR-75-
1 over a 6 day period by up to 50% and was associated with a 7-fold decrease in
IGFBP-2 secretion. Likewise, IGFBP-2 secretion by MCF-7, LY2 and ZR-PR-LT
was reduced by 1.8-6 fold and proliferation was increased by 30-40%. In contrast,
exposure to IGF-I resulted in an up to 1.4 fold (p<0.05)increase in IGFBP-2 secretion
by a tamoxifen resistant variant of ZR-75-1 (ZR-75-9al) while proliferation was
reduced by up to 55%.
These findings provide further evidence to support a growth inhibitory role for
IGFBP-2 and indicate that the development of anti-estrogen resistance and estrogen
independence results in differential changes in IGFBP-2 secretion in response to
IGF-I.
4.2
GLUCOCORTICOID MODULATION OF CYTOTOXICITY:
DIFFERENCES BETWEEN THE ROS17/2.8 AND UMR106 OSTEOSARCOMA
CELL LINES. H. Robson*', E. Anderson', SM. Shalet2 and OB. Eden3.
'Dept. Clinical Research, 2Dept. Endocrinology, 3Dept. Paediatric Oncology,
Christie Hospital NHS Trust, Manchester M20 4BX.
Multi-drug regimens, combining cytotoxic drugs with a variety of
other agents including steroids, are increasingly being used in the treatment
of paediatric malignancies. We have previously reported that the synthetic
glucocorticoids prednisolone (Pred) and dexamethasone (Dexa) attenuate
cytotoxicity and growth inhibition of normal epiphyseal chondrocytes
induced by exposure to a variety of cytotoxic drugs. Here we demonstrate
that these two agents do not have the same effects on the osteosarcoma
cell lines UMR106 (pre-osteoblasts) and ROS17/2.8 (mature osteoblasts).
UMR106 and ROS17/2.8 cells, grown in DMEM/F12 + 5%FCS, were pre-
treated with Pred or Dexa (50gg/ml) for 72h and subsequently exposed to a
variety of cytotoxic drugs in their EC20-80 range in the absence or presence
of Pred/Dexa for a further 72h. The drugs were cisplatin (cis; 0.5[tg/ml),
carboplatin (carb; 0.5gg/ml), etoposide (etop; 0.5gg/ml) and methotrexate
(MTX; 0.05gg/ml). Changes in cell number were analysed at 0, 3 and 6
days using a standard 96 well plate proliferation assay.
Etop, carb, cis and MTX killed steroid pre-treated UMR106 and
ROS17/2.8 cells at least as effectively as they killed untreated cells. Steroid
co-treatment during exposure to etop, carb and cis further significantly
enhanced cytotoxicity in ROS17/2.8 cultures by between 20-50% in most
cases. However, co-treatment of UMR106 cells failed to increase drug
cytotoxicity above that observed in either the pre-treated or control cultures.
Similarly, MTX cytotoxicity was increased 4 fold when combined with either
of the steroids in ROS17/2.8 cultures. Conversely, in UMR106 cultures the
cytotoxic actions of MTX were significantly reduced upon co-treatment with
either Pred or Dexa.
Thus, we have shown that glucocorticoid exposure of the
osteosarcoma cell line ROS17/2.8 but not the UMR106 cell line or normal
chondrocytes enhances the actions of several cytotoxic drugs. The
contrasting effects of MTX on the two osteosarcoma cell lines also suggest
that steroid-mediated alterations in chemosensitivity may be drug specific.
In conclusion, differences clearly exist within normal and malignant cell
types which may have important implications for glucocorticoid use in
clinical therapy.
4.4 THE EFFECT OF TAMOXIFEN TREATMENT ON MUC-1
EXPRESSION IN PRIMARY BREAST CANCER.
J.M. Hanson", D.A. Browell2, W.J. Cunliffe2, J.R. Young2, J.P. Pearson3, J.S.
Varma', A. Allen3, M.J. Higgs2, I. Brotherick'. Departments of 'Surgery &
3Physiology, University of Newcastle, and 2Queen Elizabeth Hospital, Gateshead.
Increased MUC-1 expression reduces cell-cell interaction, facilitating cell
detachment thus increasing metastatic potential. Tamoxifen therapy decreases
the incidence of both local and metastatic recurrence in breast cancer although
the mechanisms ofits action are notfully determined. We attempt, using a flow
cytometric method, to establish the effects of Tamoxifen therapy on MUC-1
expression.
Optimum staining methodologywas determined, rendering cells fixed but
permeable to the NCL-MUC-1 (Novocastra) antibody. Dual parameter labelling
using a Goat-anti-mouse-FlTC conjugated secondary antibodyto detectthe NCL-
MUC-1 primaryantibody and propidium iodide to determine nucleated cells from
debris were employed.
The effect of a three week preoperative tamoxifen treatment on MUC-1
expression by primary breasttumours was examined. Patients were matched for
Age, TumourGrade and Axillary Status. Patients were treated with either 20 mg
oral Tamoxffen perday (n=46) orreceived no medication (n=51) in the three week
interval between assessment and surgery. Specimens were snap frozen atthe
time of surgery. The percentage of cells expressing MUC-1 was determined
compared to an isotype control. Fluorescent bead standards were used to
quantifythe number ofequivalentsoluble fluorescent molecules of MUC-1/cell.
A lower percentage of cells expressed MUC-1 following three week
Tamoxifentreatment22%(95% confidence p = 17.3% - 27.3%) versus 31%(95%
confidence p = 25.1% - 37.2%) (p=0.03, Mann Whitney) and lower levels of MUC-
I expression were seen following Tamoxifen treatment 39,387 (31,407 - 47,331)
molecules/cell versus 52,878 (95% confidence p = 40,451 - 65,304) (p=0.03,
Mann Whitney).
We have demonstrated that MUC-1 levels can be monitored by flow
cytometry. MUC-1 levels in patients treated with tamoxifen forthree weeks prior
to operation are significantly lower than in a comparable group of patients
receiving notreatment. Tamoxifentherapyin the pre-operative period significantly
reduces the expression of MUC-I in primary breast cancer, which has been
implicated in the evolution of metastasis.14 Oral Presentations
4.5 ENHANCEMENT OF CYCLOPHOSPHAMIDE
ANTI-TUMOUR ACHIV1TY WITH BIOREDUCIT1VE
DRUGS AQ4N AND TIRAPAZAMINE. S.R.McKeown, 0. Friery.
R Gallagher, M.Murray, C.Clarkc, L.H.Patterson ., D.G.Hirst. School
Biomedical Sciences, University of Ulster, Jordanstown, N. Ireland; Dept
Pharmaceutical Sciences, De Montfort University, Leicester, U.K.
AQ4N(1,4-bis-{[2-(dimethylamino-N-oxide)ethyljamino}5,8-dihydroxy-
anthracene-9,10-dione) is a bioreductive drug which is reduced, in hypoxic
cells, to AQ4, a stable DNA-affinic cytotoxin. We have previously shown
that both AQ4N and Tirapazamine (Tira) enhance the anti-tumour effect of
a single dose of radiation'. We have now tested in vivo the anti-tumour
effect of AQ4N or Tira with cyclophosphainide (CPM) using a growth
delay assay (T50/80 tumour grown in BDF mice) or a clonogenic assay
(SCCVII tumour grown in C3H mice). Mice were treated, when the tumour
reached a size of about 150mm3, with a single i.p. dose of AQ4N (50-
150mg/kg) or Tira (25 or 50 mg/kg); CPM (50 or 100 mg/kg) was given
i.p. at known times (see below) after the bioreductive drug.
A significant increase in anti-tumour effect was observed when
either bioreductive drug was combined with CPM. In BDF mice there was
a tumour growth delay of 15.8 days with AQ4N (p = .0001) and 11.5 days
with Tira (p = .0013). Combination of CPM with AQ4N was found to be
equivalent to a single 200mg/kg dose of CPM alone i.e. a 50% reduction
in CPM dose for an euuivalent anti-tumour effect. For Tira the effect was
equivalent to 150mg/kg CPM. Normally drugs were administered 30min
apart. Administering AQ4N 6h prior to CPM showed no appreciable
difference in the anti-tumour effect obtained. A clonogenic assay weas used
to determine the effect of drug combinations in the SCCVII model. Tira
provided a dose modification factor of approximately 1.7 at 50mg/kg CPM
and about 1.4 when combined with 100mg/kg CPM (30 min or a 2.5h
interval). AQ4N provided a dose modification of > 4 with 50mg/kg CPM
and about 3 with 100mg/kg CPM (30min or 6h interval). In conclusion
both Tira and AQ4N enhance the anti-tumour effect of CPM, with AQ4N
showing a greater effect in both tumour models.
(1) McKeown SR, Hejmadi M, McIntyre IA. McAleer JJA, Patterson LH.
(1995) Br J Cancer, 72,76 - 81.
4.7 SELECTIVELY ACTIVATING BIOREDUCTIVE
DRUGS IN-VITRO USING GENE THERAPY,
M.P.Saundersl, A.V.Pattersoni, P.J.Ratcliffe2, A.L.Harris2, I.J.Stratfordl,
'Dept of Pharmacy, University of Manchester, Ml3 9P. 2Institute of
Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DU.
The treatment of patients with conventional chemotherapy is
sometimes associated with severe systemic toxicity and only a minimal
survival benefit. Because of this, attempts have been made to specifically
target the tumour, to increase cell kill but to spare the surrounding
normal tissues. Bioreductive drugs are prodrugs that are activated in
hypoxic regions of tumours by a range of reductases including
NADPH:P450 reductase. This tumour specific metabolism provides the
basis for therapeutic differential. When the cDNA for P450 redLctase,
under the control of the moloney leukaemia virus LTR, was transfected
into the MB-MDA-231 breast cancer cell line, clones over-expressing
P450 reductase were generated, which were up to 50 times more
sensitive to bioreductive drugs than the wild type cell line under hypoxic
conditions. It has previously been reported that certain sequences of
DNA can be used to drive gene expression during or following hypoxia
(Dachs et al, Nat Med 3, 5; 515-520,1997) or irradiation (Weichselbaum
et al, IJROBP 30,1; 229-234 1994). We have ligated concatimers of
regulatory sequences of cDNA to marker genes and also the gene
encoding P450 reductase in to a mammalian expression vector system.
The enhancers we have used include the hypoxia responsive elements
(HRE) of phosphoglycerate kinase 1 (PGKI) and erythropoietin (EPO)
as well as Nuclear factor kappa B (NFkB), activator protein I (AP-1) and
Early growth response gene 1 (Egr-l). Egr-l has been shown to be
radiation inducible whilst NFkB and AP-1 are potentially activated by
both stimuli. Using CD4 as a marker we have shown that a vector
containing a pentamer of the Epo HRE and the Egr-1 promoter is both
radiation inducible and hypoxically activated. We have also shown that
P450 reductase activity can be induced in hypoxic conditions when under
control of both an AP-I trimer or a NFkB/PGKI pentamer. Such clones
have been shown to be more sensitive to bioreductive drugs after
hypoxic incubation. Further evaluation of these enhancer / promoter
systens is under-way. (MPS is a MRC clinical training fellow).
4.6 HYPOXIA INDUCIBLE FACTOR-1: EFFECT ON TUMOUR
BIOLOGY, Gabi U. Dachs', Brian Marples2, Kaye J.
Williams3, Ian J. Stratford3 and Dai J. Chaplin' 'Gray Laboratory Cancer Research
Trust, Northwood HA6 2JR, 2Paterson Inst. Cancer Research, Manchester M20 4BX,
3Dept. Pharmacy, University ofManchester, Manchester M13 9PL
Solid tumours have regions of reduced oxygen (hypoxia) as they contain a poor and
disorganised blood supply. Hypoxia inducible factor-I (HIF-I) is the transcription
factor that regulates gene expression in response to hypoxia. HIF-1 binding sites
(HRE) have been found in regulatory sequences of variety of genes (Epo, VEGF,
PGK, glut-3, etc.) and HIF-1/HRE gene regulation could be demonstrated in all
mammalian cells tested to date. HIF-I is a heterodimer consisting ofHIF-lIa and HIF-
IB/ARNT basic-helix-loop-helix proteins. HIF-1J/ARNT can also dimerize with the
dioxin receptor AHR to regulate the xenobiotic response.
We have previously shown that HIF-I could regulate gene expression in solid tumours
and influence tumour growth and angiogenesis (Maxwell et al., 1997). Mouse
hepatoma cells Hepa-I containing wild type HIF-I were compared to Hepa-l c4
mutant cells which lack HIF-IP/ARNT. Xenograft tumours of c4 grew more slowly
and showed reduced vascularity compared Hepa-I wt. No difference in their growth in
vitro was observed both in air and at 1% oxygen.
To analyse the effect ofHIF-IP/ARNT on tumour biology further, the hypoxic content
of tumours was estimated by two different methods. Radiation (IOGy) followed by
single cell electrophoresis (the comet assay, Olive 1995) indicated that tumours grown
from c4 cells had a lower hypoxic fraction than those grown from Hepa-l wt cells,
since they showed more single strand DNA breaks than the wt cells. Initial in vivo
radiation sensitivity assays, however, showed no difference in surviving fraction
following lOGy radiation, although clonogenicity from the c4 tumours was only about
10 % of the wt. Clonogenicity from in vitro radiation experiments were comparable,
and c4 showed a marginal increase in sensitivity to radiation compared to Hepa-I wt.
Treatment of tumour-bearing mice with the hypoxia marker NITP (Hodgkiss et al,
1995) showed no overall difference in staining between wt and HIF-lI1/ARNT Hepa-l
tumour sections, although there was considerable intertumour variation within each
group. Oxygen measurements using polarographic and fibre optic technology are now
planned to directly determine tumour oxygen status.
4.8 BIODISTRIBUTION OF ENZYME ACTIVITY OF A FUSION
PROTEIN FOR USE IN ADEPT. S.K. Sharma*I, J. Bhatial,
R.B.Pedleyl, D.A.Readl, P. Michael2, R.W. Bodenl, K.A. Chesterl & R.H.J. Begent'
ICRC Targeting and Imaging Group,Dept. of Clinical Oncology, Royal Free & UCL
Medical Schools, London NW3 2PF. UK. 2CAMR, Salisbury.
Antibody directed enzyme prodrug therapy (ADEPT) involves targeting
of an enzyme specifically to tumour sites where it converts a relatively
non-toxic prodrug to a potent cytotoxic drug.
A recombinant fusion protein, comprising carboxypeptidase G2
(CPG2) enzyme and the anti-CEA scFv MFE-23 derived from a phage
display library, has been expressed in E. coli. The biodistribution of
enzyme activity of this fusion protein has been studied in the LS174T
human colon adenocarcinoma in nude mice in comparison with free
CPG2. Mice were injected with either MFE-CPG2 or free CPG2
,l000units CPG2/kg per mouse. Tumour, plasma and other normal
tissues were collected over time, homogenised, and in vitro turnover of
CPG2 substrate measured by HPLC. CPG2 concentration in tissue
homogenates was calculated. The percentage injected enzyme activity
per gram at 6, 24 and 48hrs in tumour was 28%, 21% and 9%
respectively for the fusion protein compared to 10.28%, 2.184% and
0.34% for the free CPG2. The corresponding plasma levels were 18%,
2% and 0.49% for the fusion protein and 10.28%, 0.87% and 1.2% for
free CPG2. This gave tumour to plasma ratios of 1.5, 10 and 19:1 for
the fusion protein and 0.77, 2.5 and 0.28 for the free CPG2 group.
Therefore at 48hrs after injection, 26 times more CPG2 was present in
the tumour with the fusion protein than with free CPG2 alone without
corresponding increase in normal tissues. The enzyme concentration
measured in tumours compares favourably with that observed with
A5B7-F(ab')2-CPG2 conjugate used in our ADEPT pre-clinical and
clinical studies with faster plasma and normal tissues than is found for
the conjugate.
Whereas the fusion protein cleared rapidly from normal tissues, high
levels of enzyme activity were retained at the tumour site, resulting in
tumour to liver, kidney and lung ratios of 371:1, 562:1 and 450:1
respectively at 48hrs. These results indicate that the MFE-23-CPG2
fusion protein has the required characteristics for ADEPT with high
tumour selectivity and efficacy.
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5.1 LOW LEVELS OF uPA IN BASAL CELL CARCINOMAS
OF THE SKIN: A POSSIBLE REASON FOR THEIR
FAILURE TO METASTASISE? T. Maguire*', D. Chin2, D.S. Souta9,T. O' Reilly'
& M.J. Duffy', 'St. Vincent's Hospital, Dublin& 2Canniesburn Hospital, Glasgow.
Urokinase plasminogen activator (uPA) is a serine protease causally involved
in cancer invasion and metastasis. In vivo, uPA acts by binding to a
membrane-bound receptor, termed uPAR, while its catalytic activity is
controlled by the inhibitor PAI-1. Basal cell carcinomas (BCC) of the skin
represent one of the most frequent forms of cancer in this country. These
tumors are unique in that they exhibit low rates of formation of distant
metastasis. We hypothesise that this inability of BCCs to give rise to distant
metastasis may be due either to low levels of uPA or high levels of PAI-1
within the BCCs. The aims of this study were, therefore, to assay uPA, uPAR
and PAI-1 within the BCCs and to compare these concentrations with levels
present in other skin tumors such as squamous cell carcinomas (SCCs) and
malignant melanomas and also with levels in benign skin lesions.
uPA, uPAR and PAI-I were extracted from benign skin lesions (n=45), BCCs
(n=52), SCCs (n=26) and malignant melanomas (n=16) using 1% Triton X-
100 in a 50 mM Tris-HCl buffer (pH 7.4) and then assayed by ELISA
(American Diagnostica). Protein levels were estimated using the BIORAD
assay.
Median levels of uPA were similar in benign lesions (0.053 ng/mg) and
BCCs (0.063 ng/mg). uPA levels, however, were significantly higher in both
SCCs (0.169 ng; p=0.0031l) and malignant melanomas (0.572 ng/mg;
p=0.0001) compared to concentrations in BCCs. Similarly, levels of uPAR
were significantly higher in SCCs and malignant melanomas compared to
BCCs. Finally, median levels of PAI-I were lower in the BCCs (0.927
ng/mg) than in SCCs (1.465 ng/mg; p=0.080) and were approximately 5
times lower in the BCCs compared with malignant melanomas (p=0.0001).
We conclude from this study that the failure of BCCs to metastasise is
unlikely to be due to the presence of excessive levels of PAI-1. On the other
hand, the findings of this study suggest that low levels of uPA, its receptor
(uPAR) and perhaps PAI-1 contribute to the low metastatic potential of
BCCs.
5.3 MATRIX METALLOPROTEINASES ARE
OVEREXPRESSED IN COLORECTAL CANCER.
H.M. Collins*, G.M. Tierney, S.A. Watson.
The Academic Unit ofCancer Studies, Department of Surgery, University
Hospital, Nottingham.
Introduction: Matrix Metalloproteinases (MMPs) are a family of
proteolytic enzymes which work in concert to degrade components ofthe
extracellular matrix. These invasive enzymes have been implicated in
colorectal cancer progression. Their action is regulated by the naturally
occurring inhibitors, TIMPs.
Aims: To establish a quantitative profile of MMPs and TIMPs in paired
normal mucosa and colorectal carcinomas.
Methods: Normal and tumour samples were obtained from patients
undergoing routine resection. mRNA was extracted from tissue using
guanidium thiocyanate, purified and reverse transcribed to double stranded
cDNA. Competitive PCR was performed with the following primer pairs;
MMP's-l,-2,-3,-7,-9,-10,-1, MT-MMP-1,-2, TIMPs -1,-2 and GAPDH.
The technique relies on a competition reaction in which a synthetic multi-
competitor cDNA standard is co-amplified with target cDNA in the same
PCR reaction. MMP mRNA levels were expressed relativeto GAPDH.
Results: mRNA was detected for all the MMPs and their inhibitors in the
tumour samples. Levels were lower in the normal tissue with MMP-10
detected in only one sample. Levels were significantly different in the
tumour samples when compared to normal tissue for MMPs -1, -3, -7, -9
and -1 (p = 0.0294, p = 0.0294, p= 0.0304, p= 0.0304, p= 0.0294, Mann
Whitney U non -parametric test). MMP-2, the membrane type
metalloproteinases and their specific inhibitors were not significantly
different.
Conclusions: 'Net proteolytic' activity is potentially greater in the tumour
samples which may be significant in the progression ofcolorectal cancer.
5.2 DIFFERENTIAL UPREGULATION OF MMP-9 IN SQUAMOUS
CELL CARCINOMAS OF HEAD AND NECK BY EGFR
LIGANDS. P. O'charoenrat, S. Eccles, W. Court, G. Box, H. Modjtahedi and C. Dean.
McElwain Laboratories, The Institute of Cancer Research, Sutton, Surrey SM2 5NG.
Squamous cell carcinomas ofthe head and neck region are characterised by a marked
propensity for local invasion and dissemination to cervical lymph nodes; distant
metastases are found in 30-40% of cases. Tumours over-expressing the epidermal
growth factor receptor (EGFR) and/or one or more ofits ligands (EGF, TGFa, HB-
EGF, amphiregulin and betacellulin have a higher probability of invasion and
metastasis. Matrix metalloproteinases (MMPs) are key enzymes involved in not only
invasion of tumour cells through stroma and endothelia during extravasation of
secondary sites, but also in the penetration of capillary sprouts during
neoangiogenesis, critical steps in metastasis development. We set out to examine, in
established squamous cell carcinoma cell lines (e.g HN5, HN6, Detroit 562, RPMI
2650) and in cells newly derived from patients with head and neck cancer (ICRO06),
the relationship between EGFR expression and MMP (particularly gelatinase)
activity, and the effects of different EGFR ligands. We found that the levels of
MMP-9 (gelatinase B) pro-enzyme and active enzyme was highest in cells with the
highest EGFR expression as judged by zymography. Similar results were seen with
MIMP-2 (gelatinase A), although the enzyme levels were lower, and active enzyme
was rarely seen. Incubation ofthe cell lines with EGFR ligands upregulated MMP-9
(but not MMP-2) expression in a dose dependent manner, the effects being most
marked in cells with high EGFR, and negative in cells with no over-expression ofthis
receptor. In addition, we found that betacellulin consistently increased MMP-9
expression and activation more than the other four ligands when tested at equimolar
concentrations. All ligands induced morphological changes in HN5 carcinoma cells,
consistent with an "epithelial-mesenchymal transition" and increased motility. The
ligands had no demonstrable direct effect on the MMP profiles offibroblasts derived
from head and neck cancers which showed constitutive expression of latent and
active MMP-2. However, co-culture of fibroblasts and tumour cells also led to
increased MMP-9 activity, consistent with previously described paracrine
interactions. Further work will aim to define the effects of specific EGFR ligands on
other members of the MMP family in larger panels of squamous cell carcinomas;
characterise their invasive capacity, and examine the potential therapeutic effects of
monoclonal antibodies and MMP inhibitors.
5.4 INCREASED EXPRESSION OFGELATINASES (MMP-2 & MMP-9)
IN HUMAN COLORECTAL CANCER, C Keh*' 3, T Ismail', PG de
Takats', A Martin3, MJO Wakelam3 and DJ Kerr3. 'Dept. of Surgery , 'CRC Institute for
cancer Studies, University Hospital, Birmingham B15 2TH, 2Oncology Centre,
Addenbrooke's Hospital, Cambridge, CB2 2QQ.
In colorectal carcinogenesis, it appears that normal epithelial cells undergo dysplastic
change to form a benign tumour (adenoma), which, over time, becomes malignant.
Malignant progression requires degradation of basement membrane to facilitate invasion
into surrounding tissues. The matrix metalloproteinases, MMP-2 (gelatinase A) and
MMP-9 (gelatinase B) degrade type IV collagen, the main component of basement
membrane and may play a role in tumour invasion and metastasis. We undertook to
determine the relationship between gelatinase expression and malignant transformation
in human colorectal cancer.
100 paired colorectal tumour and normal mucosa samples were fresh-frozen and
homogenised prior to analysis. Gelatinase content was measured by zymography and
quantitated by computer assisted densitometry. Both the inactive 72kDa proform and
cleaved, active 62 kDa form of MMP-2 could be detected, while only a single band
representing the inactive form of MMP-9 was evident. Statistical analysis of tissue
gelatinase content was performed by comparing the paired normal with tumour samples
using Wilcoxon signed rank test and correlating the tumour/normal ratios with tumour
P ogression (ie. normal, adenoma, carcinoma and Dukes' stage).
Tumour stage MMP-2 MMP-2 MMP-9
proenzyme active form proenzyme
Adenoma (n=7) 1.15 (p=0.17) 1.39 (p=0.38) 1.28 (p=0.I 1)
Dukes' A (n=15) 1.55 (p=0.005) 2.46 (p<0.005) 2.08 (p=0.001)
Dukes' B (n=34) 1.14 (p=0.01) 3.10 (p=0.0001) 2.05 (p=0.0001)
Dukes' C (n=44) 1.24 (p<0.05) 3.08 (p=0.0001) 1.70 (p=0.0001)
Median tumour/normal ratios of MMP-2 and MMP-9 activities shown
MMP-2 and MMP-9 were present in higher amounts in tumour tissue compared with
normal mucosa in all cases. This was not statistically significant for adenomas, probably
reflecting small numbers analysed. There was however, a trend towards a correlation
between increasing active MMP-2 content and tumour progression (ie. normal versus
adenoma versus carcinoma). There was no significant correlation with Dukes' stage.
MMP inhibitors are currently being tested in clinical trials of cancer patients. However
their clinical application is being hampered by systemic toxicity which may be
attributable to lack of specificity against a particular class of MMP. Our study supports
development of specific gelatinase inhibitors which may afford greater clinical utility.16 Oral Presentations
5.5 THE EFFECT OF ADENOVIRAL GENE TRANSFER OF
MMP AND TIMP ON A RENAL CELL LINE. A.M McElligott*, A.H. Baker' &
H. McGlynn, School of Biomedical Sciences, University of Ulster, Coleraine BT52
ISA, 'Bristol Heart Institute, Bristol Royal Infirmary, Bristol BS2 8HW.
The ability ofa cancer cell to invade tissue surrounding the tumour is a critical step
in the metastatic process. The extracellular matrix (ECM) forms a physical barrier
to this tumour cell invasion. Members of the matrix metalloproteinase (MMP)
family of extracellular endopeptidases are the only known enzymes capable of
degrading native collagens and therefore play the primary role in ECM remodelling,
and have been implicated in the metastatic process in some cancers. The activity of
MMPs is tightly regulated with important negative regulators being the tissue
inhibitors of metalloproteinases (TIMPs). In this study we have used recombinant
adenoviral vectors to transfect the renal cell carcinoma cell line, caki-I, with the
genes for MMP-9 and TIMP-I and -2. Increases in MMP-9 and TIMP-I and -2
levels were determined by RT-PCR, gelatin zymography, immunoblotting and
quantitative ELISA. The effect of increasing the expression of these genes on the
invasive potential of the caki- I cell line was investigated using an ini vitro invasion
assay which determines the ability of the cells to degrade and migrate through an
ECM boundary. The invasive potential of the cells was shown to be altered
following transfection with the MMP and TIMP genes. In particular the cells
showed a dose responsive decrease in invasion potential dependent on the
multiplicity of infection with adenoviral vector for the TIMP genes. These results
suggest that MMP-9 and TIMP-I and -2 have a role in the invasive ability of the
caki-I cell line and that recombinant adenoviral vectors are an efficient system for
studying the role of MMPs and TIMPs in this process in vitro. These vectors will
be a useful tool for int i'ivo studies of the role of MMPs and TIMPs in the invasive
and metastatic process.
5.7 Tumor Promoters, TPA and Okadaic acid, Regulate
the Expression of ce211 Integrin, *Nissinen, L.,
Westerimarck, J., Koivisto, L., Kdhiri, V-M. and Heino, J., MediCity
Research Laboratory, University ofTurku, Turku, Finland.
Integrin (u2pl is a heterodimeric transmembrane receptor for various
collagen types and, at least in some cell types, for laminin and tenascin.
We have shown, that in osteogenic cells the expression of cx2pl integrin
is induced by both Kirsten sarcoma virus and chemical transformation
(Santala et ail., J. Biol. Chern. 269: 1276-1283, 1994). The association
of tx2 integrin with transformed cell phenotype was studied further.
(ui3 integrin is a type I collagen receptor of human osteogenic MG-63
cells. In the presence of TPA MG-63 cells showed increased adhesion
on type I collagen, whereas okadaic acid decreased the attachment of
cells to several matrix molecules, including type I collagen. As shown
by hlow cytometry okadaic acid had little effect on the cell surface
expression of e(2 integrin subunit although its mRNA levels and the
synthesis of the corresponding protein increased. TPA was potent
inducer of ce2 integrin expression at protein and m-RNA level. The
induction of (x2 integrin was seen also on cell surface. The two agents
had opposite effects on the (x3 integrin; TPA induced and okadaic acid
suppressed its expression. expression. Nuclear run on assay showed,
that in MG-63 and HT-1080 cells oc2 integrin gene is regulated at
transcriptional level by TPA and okadaic acid. Dexamethasone, which
is a potent AP-I inhibitor, prevented the effect of both factors on ce2
integrin expression. Transient transfection assays with cx2 integrin
promoter and tan AP- 1-dependent control promoter linked to a reporter
cene, as well as experiments with cells lines other than MG-63,
indicated that AP- I activation alone does not explain the induction of ce2
integrrin gene expression.
5.6 SIGjNALLING FROM THE P, INTEGRIN ANt) 1iEPATOCYTE 5.6 (GROWTH FACTOR IN TWO METASATIC CELL LINES: A ROLE
IN CELL MOTILITY AND INVASION, V.G. Brunton, 1.
McNairn. A.W. Wyke and M. Frame, Beatson Institute for Cancer Research, Garscube
Estate, Swvitchback Road, Glasgow G61 IBD.
Two cell lines were established from metastatic lesions taken from the liver (ALT-F)
and the lymph node (ALT-G) of a patient harbouring a primary colon tumour
(Gregoire et al., Inv. Metast. 13:253,1993). Differences in the ability ofthese two cell
lines to move in a wound healing assay and invade in vitro into Matrigel in response
to hepatocyte growth factor (HGF) were observed. The ALT-G cells were able to
move and invade in response to HGF while the ALT-F cells were not. Both cell lines
were able to respond mitogenically to HGF indicating that a downstream component
of the HGF signalling pathway that can distinguish between a mitogenic and
motogenic response may be altered in the two cell lines. Integrins allow cells to
adhere to extracellular matrix proteins and are involved in both the invasion and
motility of cells. An antibody to the P integrin was able to block HGF induced
motilits and invasion in the ALT-G cell line. As a number of studies have indicated
that cross-talk occurs between integrin and growth factor signalling pathways we
decided to look at this in our two cell lines. HGF and a P integrin signal induced
phosphors lation of focal adhesion kinase and activation of MAP kinase in both cell
lines. No synergistic response was seen in the presence ofboth HGF and a PI integrin
signal. Furthermore HGF treatment did not alter the expression of a number of
integtrin sub-units including P integrin.
We are currently looking at other downstream components of these signalling
pathways such as p130"' and c-Src to determine whether differences do occur
between the cell lines which may account for the differences observed in the motility
and invasion ofthe two cell lines.
5.8
INTERLEUKIN-1 UPREGULATES EXPRESSION OF CD44 AND ITS
METASTASIS-ASSOCIATED VARIANT V6 IN THE HUMAN
ENDOTHELIAL CELL LINE ECV304 BY A MECHANISM INVOLVING THE
TRANSCRIPTION FACTOR EGR-1. K. Fitzgerald and L.A.J., O' Neill, Dept.
Biochemistry and Biotechnology Institute, Trinity College, Dublin 2.
Tumour cells may acquire, and use for their metastatic spreading,
properties which lymphoid cells have developed to defend against pathogens.
The cell adhesion molecule CD44 is a ubiquituously expressed
multifunctional glycoprotein, involved in lymphocyte-endothelial cell
interactions (as a lymphocyte homing molecule), cell adhesion, T-cell
activation and tumour metastasis. Here, we identify CD44 as a downstream
target of the pro-inflammatory cytokine interleukin- 1, (IL-1), in the
endothelial cell line ECV304. IL-I increased expression of the 85 kDa standard
CD44 above basal levels. Interestingly, a 180-200 kDa CD44 variant 6 isoform,
(which has been linked with tumour metastasis [1] was also upregulated, as
determined by ELISA and western immunoblotting. Analysis of mRNA
expression by RT-PCR and northern blotting using CD44 standard and variant
exon 5 specific primers indicated that IL-1 increased CD44 gene transcrption.
Transfection of CD44 promoter- reporter constructs demonstrated an induction
of transcriptional activity following treatment of cells with IL-Ice. The EGR-1
binding motif within the promoter was shown to be necessary for stimulus-
induced expression as mutation of this site abolished transcriptional activity
following treatment with IL-icl. Egr-I protein accumulated following IL-1
treatment and IL-1 was shown to activate Egr-i consensus site-specific DNA
binding, as shown by carrying out an electrophoretic mobility shift assay with
a probe containing the Egr-1 binding site. Taken together, these studies identify
EGR-1 as an intermediary linking IL-1 receptor derived signals to the induction
ofCD44.
[1] Gunthert U., Hofmann, M., Rudy, W., Reber, S., Zoller, M., Haubmann, I., Matzku,
S., Wenzel, A., Ponta, H., and Herrlich, P. 1991, Cell (65), 13-24.
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5.9 DISSASSEMBLY OF ENDOTHELIAL CELL-CELL
ADHERENS JUNCTIONS FOLLOWING
ADHERENCE OF HUMAN BREAST ADENOCARCINOMA CELLS.
J. Cai, W.G. Jiang and R.E. Mansel, Metastasis Research Group, Department
ofSurgery, University ofWales College ofMedicine, Cardiff. CF44XN.
Tumour cell extravasation from the circulation is accompanied by an increase
in the permeability ofthe vascular endothelium. Adherens junctions play a key
role in the maintenance of endothelial cell permeability and are comprised of
the vascular endothelial (VE)-cadherin/catenin adhesion complex. In this
study, the human breast cancer cell line, MDA MB231, was co-cultured with a
monolayer of human umbilical vein endothelial cells (HUVEC) and the
resultant effects on the endothelial adherens junction integrity investigated.
Using immunofluorescence analysis we observed that, following tumour cell
adherence to the HUVEC, there was a rapid (within 5 minutes) redistribution
of VE-cadherin, resulting in its loss from regions of endothelial cell-cell
contact. These effects were transient since VE-cadherin gradually reorganised
within the endothelial cell contacts after this time. Following
immunoprecipitation of VE-cadherin from the HUVEC cultured with MDA
MB231 for different time periods (Omin, 5mins, 30mins and lhr) and
subsequent immunoblotting, we observed that the overall expression ofVE-
cadherin did not change, however, the amount of P-catenin markedly
decreased afterSmins oftumour cell adhesion to the HUVEC. Immunoprobing
of these samples with anti-phosphotyrosine antibodies demonstrated that the
tyrosine phosphorylation ofVE-cadherin was significantly increased following
Smins of tumour cells adhesion. Together, these results suggest that the
adhesion of tumour cells to HUVEC promotes the redistribution of VE-
cadherin from inter-endothelial adherens junctions, an effect which may be
attributed to the increase in tyrosine phosphorylation of members of the VE-
cadherin/catenin adhesion complex. This, in turn, may increase vascular
endothelial permeability and facilitate the transendothelial migration of
tumour cells during extravasation.
6.1
SENESCENCE BY AN INK4 AND P53-DEPENDENT MECHANISM. J.Munro,
H.Ireland, V.Morrison and E.K Parkinson*, CRC Beatson Laboratories, Garscube
Estate, Switchback Rd. Bearsden, Glasgow, U.K.
The histone deacetlyase inhibitor sodium dibutyrate (SDB) has been
reported to cause a phenotype that is biologically reminiscent of senescence
in human fibroblasts (Ogryzko et al, Mol. Cell Biol., 16, 5210-5218, 1996)
but remarkably little is known of its mechanism of action. We have extended
the earlier observations to show that SDB produces a phenotype which is
biologically, biochemically and genetically inseparable from replicative
senescence. In particular, theSDB-treated cells upregulated the cell cycle
inhibitorsp21wl andpl64"" in the same sequential order as in senescence
and the cyclins A, B and their associated kinases cdc2 and Cdk2 were
downregulated, resulting in an underphosphorylation of pRb and a GI arrest.
Significantly, p53 protein was not induced, and this, together with the
observed accumulation of pl6 ink inSDB-treated fibroblasts argues against
the results being a consequence of DNA damage. The programme was
severely abrogated by SV40 Tantigen in both human and mouse fibroblasts
and in most established cell lines. Experiments with nullizygous mouse cells
showed that both the ink4 locus and p53 were required for optimum inhibiton
of proliferation but that p21-deficient cells were sensitised toSDB-induced
apoptosis which normally occurs at much higher doses. The results indicate
thatSDB may mimic a form of senescence that does not require telomeric
attrition or that it replicates signals generated by one or more shortened
telomeres. We propose that SDB could be a useful tool in the investigation of
the molecular pathways involved replicative senescence.
5.10 EXPRESSION OF THE SERPINS SCCA AND LEUPIN
IN NORMAL AND MALIGNANT SQUAMOUS EPITHELIUM OF THE
UTERINE CERVIX. J. Coulter*, R.C. Barnes and D.M. Worrall.
Department of Biochemistry, University College Dublin, Dublin 4, Ireland.
At present there is no reliable tumour marker to aid the gynaecological
oncologist in the management of patients with carcinoma of the uterine
cervix. One protein which has been investigated as a tumour marker is
the squamous cell carcinoma antigen (SCCA) which is a member of the
serpin superfamily of protease inhibitors. Serum levels of SCCA can
correlate with late stages of disease and a role for SCCA in tumour
development has been proposed. An immunoassay detection system for
serum SCCA has been developed but its sensitivity and specificity are
unclear.
We have discovered a related serpin in HeLa cells, leupin, which is high in
sequence identity (92%) to SCCA, but which contains differences in the
serpin reactive loop sequence.(Barnes, R.C. and Worrall, D.M. (1995)
FEBS Lett., 373, 61-65). The degree of sequence similarity between the
two serpins means that previous patient studies on SCCA expression are
likely to have detected both SCCA and leupin. We have evidence that the
IMx serum immunoassay for detection of SCCA will also detect leupin,
and that leupin may be the fraction previously considered to be an acidic
isoform of SCCA. An ability to distinguish between these gene products
may provide better insight into their potential role in tumour development
and lead to greater efficacy in tumour marker detection.
In this study we have designed specific oligonucleotide primers to detect
the individual expression of SCCA and leupin in human tissues. Biopsies of
normal and malignant uterine cervix squamous epithelium were excised
from patients at the time of hysterectomy and both genes were amplified
from total RNA by RT-PCR. Both leupin and SCCA are expressed in normal
and malignant squamous epithelium of the uterine cervix. However, SCCA
levels were greater in normal cervix, and although both gene products
were elevated in tumour tissue, leupin showed a more significant
increase. These findings suggest that leupin may be a more important
marker for cervical carcinoma.
6.2 CLONING AND CHARACTERISATION OF HUMAN AND
MOUSE TELOMERASE RNA GENE PROMOTER
SEqUENCES. W. Nicol Keith,*' Jiang-Qin Zhao', Stacey F. Hoare', Robert McFarlane2, Sharon
Muir, Kenneth Parkinson2, Donald M. Black2. 'CRC Dqetnat of Medical Onwology, Univesity of
Glasow, 2Beatsn Instiae, CRCBealson abs, GaMscube Est, Swiadc Rd.BeaXsde, GlasgowG6l1BD,UK,
Variation in telomerase activity is correlated with cellular senescence and tumour
progression. However, although the enzymatic activity oftelomerase has been well
studied, very little is known about how expression oftelomerase genes is regulated
in mammalian cells. We have therefore cloned the promoter regions ofthe human,
(hTR), and mouse, (terc), telomerase RNA genes in order to identify the regulatory
elements controlling telomeraseRNA gene transcription. 1.76kb encompassing
the hTR gene promoter region was sequenced, as was 4kb encompassing the terc
promoter. No significant sequence similarity could be detected in comparisons
between human and mouse 5'-regions, flanking the transcribed sequences.
However, both the human and mouse telomerase RNA genes are within CpG
islands and may therefore be under the regulation of DNA methylation. Transient
expression of hTR-reporter gene constructs in HeLa and GM847 cells identified
the elements responsible for promoter activity are contained in a 231bp region
upstream ofthe transcriptional start site. Transient expression of terc-reporter gene
constructs in 3T3 and A9 cells identified the elements responsible for promoter
activity are contained in a 73bp region upstream of the transcriptional start site.
These studies have implications for our understanding of the signal transduction
pathways linking telomere attrition to proliferation, cellular senescence,
differentiation and oncogenesis and for the development of novel transcription
targeted cancer therapies.18 Oral Presentations
6.3
WITHDRAWN
6.5 A NOVEL P53 BINDING SEQUENCE IN INTRON 3 OF
THE HUMAN MDM2 PROTO-ONCOGENE: A PUTATIVE
ADDITIONAL P53-DEPENDENT PROMOTER, H. Liang* and J. Lunec,
Cancer Research Unit, University of Newcastle upon Tyne, NE2 4HH, U.K
The MDM2 proto-oncogene exhibits a complex pattern of expression,
producing a number of overlapping transcripts which differ by site of
initiation of transcription and by alternative splicing of internal exons. So far
two promoters (P1 and P2) have been identified. The P1 promoter is
located upstream of exoni and induces transcripts initiating at the first base
of exon 1 in a p53-independent manner. The P2 promoter is located near
the 3' end of intron 1 and produces transcripts starting at the third
nucleotide of exon 2 in a p53-dependent manner. Since the coding of this
gene starts from exon 3, these two promoters would generate transcripts
with identical translation potential.
In the process of human MDM2 genomic sequence mapping, we have
identified a promoter-like region near the 3' end of intron 3, including a
TATA box (TATAATA) 28 base pairs upstream of exon 3 and also four
motifs upstream of this exon, which show a good match to the consensus
p53 binding sequence. To test whether there is another p53-dependent
promoter in intron 3, by which a transcript lacking part of the p53 binding
domain sequence is expected to be generated, a number of the
experiments have been performed. Electrophoretic mobility shift assays
(EMSA) displayed that the mobility of the DNA fragment in this region is
retarded in the presence of p53 and p53 antibody (pAB421) gives a super-
shift. The binding of p53 to this DNA fragment was competed out by excess
non-labelled specific DNA but not non-specific DNA.
Immunoprecipitation/DNA-binding assays also showed specific p53 binding
consistent with the EMSA results. In DNA footprinting experiments, TATA
binding protein (TBIID) was observed to protect from DNAse digestion in
the putative TATA box region. Taking all together, we conclude that p53
binds to intron 3 of the human mdm2 in a sequence-specific manner We
are carrying further studies, including reporter gene experiments and the
identification of truncated transcripts corresponding to this putative
promoter.
6.4 2,6-DISUBSTITUTEDAMIDO- ANTHRACENE-9, 10 DIONES:
SMALL MOLECULE INHIBITORS OF HUMAN TELOMERASE, L R. Kellandc'.
S.M. Gowan', P.J. Perry2 and S.Neidle2. 'CRC Centre Cancer Therapeutics and 2CRC
Biomolecular Structure Unit, Institute ofCancer Research, 15 Cotswold Road, Sutton,
Surrey SM2 5NG, UK.
Interest in telomerase, a reverse-transcriptase enzyme possessing its own RNA
template and responsible for maintaining the repeat telomeric sequences on the ends of
chromosomes, has increased substantially in recent years, both in a diagnostic and
therapeutic setting. Around 85% of tumours exhibit telomerase expression while
expression is absent in the majority of somatic cells; high telomerase activity has been
shown to correlate with poor prognosis in some tumour types; telomerase activation
has recently been directly shown to be involved in bypassing cellular senescence.
Hence, potent and selective inhibitors of telomerase may provide a novel tumour-
selective target for anticancer drug design. The telomeric repeat sequence in humans is
5'-TTAGGGn, a guanine-rich sequence capable of forming G-quadruplex four-
stranded DNA structures. We have adopted a telomerase-inhibitorv strategy aimed at
the design of small molecules capable of stabilising G-quadruplexes and thereby
preventing the requirement of telomerase for a non-folded telomere DNA primer. A
series of compounds based on 2-6 disubstituted amido-anthracene-9, 10-dione
derivatives, shown to form G-quadruplex complexes with telomeric DNA, have been
evaluated for telomerase inhibitory and in vitro growth inhibitory properties against
human ovarian carcinoma cell lines. The initial biological evaluation of putative
inhibitors examined the selectivity of polymerase versus telomerase inhibition by
testing the ability of compounds to inhibit Taq polymerase in a cell-free assay. While
the anthraquinone-based anticancer drugs doxorubicin and mitoxantrone were potent
inhibitors of Taq polymerase at 10pM, some of the novel disubstituted derivatives
exhibited no inhibition at either 10 or 5OpM. Moreover, these "polymerase-negative"
compounds showed a range in their ability to inhibit human telomerase in an in vitro
cell-free PCR-based assay (e.g., 50% inhibition at concentrations ranging from 4.5pM
for BSU102I to >5OpM for BSU1032). Parallel growth inhibition studies (96h drug
exposure, sulforhodamine B assay) have shown the 2-6 disubstituted compounds to be
substantially less cytotoxic than doxorubicin (mean IC50 of approx 10nM) or
mitoxantrone (mean IC50 of approx 0.5nM) with IC~5 values typically in the 0.5 to
5pM range. Interestingly, long-term culture of the A2780 cell line with sub-cytotoxic
concentrations of one of the complexes, resulted in detectable telomerase inhibition
from 18 days onwards with a maximum inhibition of 400'o at 30 days concomitant with
a marked decrease in cell -rowth. These small molecule inhibitors of telomerase
represent promising leads %vorth\ of further in vitro and it? vivo antitumour evaluation.
6.6
p53 - INDEPENDENT APOPTOSIS IN HUMAN B CELLS TREATED
WITH GENOTOXINS. Mark Wade and Martin J. AlIday. Department of Virology and Cell
Biology and Ludwig institute for Cancer Research, Imperial College of Science Technology
and Medicine, St Mary's Campus, Norfolk Place, London W2 1 PG.
The DNA damage induced by genotoxins is known to activate
p53, an established effector of apoptosis in many cell systems. We
are currently investigating the responses to a range of genotoxins
in a number of B cell lines. Surprisingly, in several Burkitt's
lymphoma (BL) cell lines carrying mutant non - functional p53
(defined by its inability to transactivate target genes or induce
apoptosis in a heterologous system), apoptosis was induced by a
range of genotoxins. Associated with morphological changes such
as nuclear condensation and fragmentation, and membrane
blebbing, we observe cleavage of poly ADP - ribose polymerase
(PARP) but not, however, appearance of a sub - G, DNA peak in
FACS analysis. Initial data from experiments combining TUNEL
and cell cycle analysis by flow cytometry suggests this is because
apoptosis is initiated from G2/M phase of the cell cycle. Western
blot data indicates no change in steady state levels of p53 and
members of the bcl - 2 family, including bcl - 2 and bax.
We have also examined similar responses in one of these lines
which has been latently infected with EBV. In contrast to its non -
infected parental line, we find this convert to be relatively
resistant to genotoxin - induced apoptosis as measured by PARP
cleavage and FACS analysis. One (or a combination of) the 9
latent EBV gene products protects cells from this p53 -
independent pathway. Candidate pathways which may activate
this p53 -independent apoptosis induced by DNA damage are
currently being investigated.Oral Presentations 19
6.7 EFFECTS OF P53 AND P16 TRANSFER IN PANCREATIC CANCER CELLS, P. Ghaneh*, M. Humphreys', W.
Greenhalf , N.R. Lemoine2, J.P. Neoptolemos', 'Dept. of Surgery, Royal Liverpool
Hospital, Liverpool, 21CRF Molecular Oncology, Hammersmith Hospital, London.
Pancreatic cancer remains relatively resistant to present regimens of
chemotherapy and radiotherapy. New and potentially more effective treatments
may need to focus on the molecular basis of the disease. Pancreatic cancer
displays significant and consistently high levels of loss of function of the tumour
suppressor genes p53 (76%) and p16 (82%). Both influence cell cycle control
and promote G1 arrest. P53 transactivates the universal cyclin inhibitor p21 and
p16 encodes a protein which inhibits CDK4 and 6 thereby preventing
hyperphosphorylation of the retinoblastoma protein (pRb) and further progression
through the cell cycle. P53 also has a major role in p53-dependent apoptosis.
The aim of this study was to replace wild-type p53 and p16 into pancreatic
cancer cell lines and assess the subsequent effects on cell growth and cell death.
Human pancreatic cancer cell lines BxPc3, Panci, MIAPACA (all homozygously
deleted for p16 and LOH p53), CFPAC1 (wild-type p16 and LOH p53) were used.
The cell lines Hep2 (wild-type 53), SW620, and FF1 (wild-type p16 and p53)
were used as control cell lines ie. with functional wild-type genes. Transfer of the
gene of interest into the cells was achieved using adenovirus vectors expressing
either wild-type p53 or p16 under control of a CMV promoter. Cells were grown
under routine tissue culture conditions and infection was carried out at a MOI of
50-100. Control infections were carried out using adenovirus expressing f-
galactosidase and phosphate buffered saline (PBS) was used for mock
infections. Expression of the therapeutic genes was confirmed using PCR, rt-
PCR, western blotting and immunofluorescence. The efficacy of gene transfer
was assessed using X-gal staining. Cell counts based on trypan blue exclusion
were used to calculate cell growth curves for 7 days following infection. Cell cycle
distribution was assessed using flow cytometry. Apoptosis was confirmed by
DNA laddering and TdT labelling. Transfer of wild-type p53 resulted in growth
inhibition rates of 78 91% (n=3+3). Transfer of wild-type p16 resulted in growth
inhibition rates of 66 83% (n=3+3). P16 transfer induced G1 growth arrest in all
cell lines resulting in a significantly high GUS ratio (p<0.001) when compared
with control infection. The apoptosis index, using TdT labelling, following transfer
of p53 was significantly increased (p<0.004) when compared with control
infections. The transfer of p16 also resulted in a significant increase in apoptosis
(p<0.03). In conclusion adenoviral-mediated transfer of wild-type p53 and p16
resulted in significant growth inhibition and increased rates of apoptosis in
human pancreatic cancer cells. This approach may represent a future therapy for
pancreatic cancer.
6.9 THE ROLE OF FUNCTIONAL P53 IN CISPLATIN
CHEMOSENSITIVITY IN A PANEL OF HUMAN OVARIAN
CANCER CELL LINES. Ml Walton*, P Koshy, CJ Medlow, S Sharp, L R
Kelland, S Sharp and J Titley. CRC Centre for Cancer Therapeutics, ICR,
15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
The tumour suppressor protein p53 is involved in cell cycle checkpoint
control and apoptosis. It is the most frequently mutated gene in human
cancer but its role in chemosensitivity is unclear. We have determined the
functional p53 status of a panel of human ovarian cancer cell lines in order
to explore its relationship with cisplatin chemosensitivity. P53 functional
status was determined by measuring p53 protein induction and p21WAFR/CIP1
and MDM-2 mRNA induction 4h following 5Gy irradiation. G1/S checkpoint
integrity was determined by measuring bromodeoxyuridine incorporation
16h forlowing 5Gy. Cisplatin cytotoxicity was measured by 96h
sulphorohodamine growth delay assay. Cisplatin uptake was determined
using flameless atomic absorbance. Mutations were identified by SCCP
and direct PCR sequencing of exons 5,6, 7 and 8 of genomic P53. A2780
and CH1 showed marked (7-15-fold) induction of p53 protein, p21WAF1/C1P1
and MDM-2 mRNA 4h following irradiation, consistent with a wild type
phenotype. PXN94 showed minimal protein induction but 3-4 fold induction
of p21WAF1'C1P1 and MDM-2 consistent with a a partial wild type p53 function.
HX62 showed stable overexpression of p53 protein and no gene induction
consistent with a mutant phenotype. Both 41M and SKOV-3 showed no
detectable protein expression or induction of p21l" 'P1 or MDM-2 and
there was no detectable P53 mRNA in either line consistent with a null p53
status. Studies of the G1/S checkpoint supported the above conclusions.
Sequencing confirmed that A2780 and CH1 were wild type, that HX62 had a
point mutation in exon 8, 41M had a deletion in exon 6. Both PXN 94 and
SKOV-3 exhibited wild type sequence in exons 5-8. The cisplatin 2h IC50
values were 5.7+0.9, 2.8+1.0, 19.1+5.2, 81.8+23.4, 5.1F2.3 and
38.3F12.6uM (meanwSD, n=3) for A2780, CH1, PXN94, HX62, 41M and
SKOV-3, respectively. There was an indication that cisplatin sensitivity
correlated with p53 functional status and was also dependent on drug
uptake. BCL-2 expression was detected in two cisplatin sensitive lines (41 M
and CHI1) but none of the others. In conclusion cisplatin chemosensitivity is
dependent on several factors including p53 functional status and drug
uptake in this panel of human ovarian cancer cell lines.
6.8 TP53 AND RELATED PROTEIN EXPRESSION IN
PRIMARY AND METASTATIC NEUROBLASTOMA D A Tweddle*l,2, A J
Malcolm3, M M Reid4, M Cole5, J Lunec2 and A D J Pearson'. Departments of
Child Health,' Cancer Research Unit2, Pathology3, Haematology4 and
Statistics5 University of Newcastle, NE2 4HH, U.K.
Backaround Wild-type TP53 has been reported to be overexpressed and
abnormally located in the cytoplasm of undifferentiated neuroblastoma.
Aims This study further investigates TP53 and related protein expression in
neuroblastomas pre and postchemotherapy (Pre-C and Post-C) and compares
primary tumour expression with bone marrow metastases Pre-C.
Methods 30 formalin fixed paraffin-embedded neuroblastoma tumours Pre-C
(all stages), 26 Post-C (16 Pre-C and Post-C) and 32 bone marrow trephine
biopsies (stage 4) (16 with primary tumour also) were studied by
immunocytochemistry for TP53, Ki-67, WAF-1 BCL-2 and BAX. Tumours were
scored positive for TP53 if >10% cells immunostained using DO-7 and DO-1
antibodies.
Results In 30 tumours Pre-C, nuclear TP53 positivity was related to adverse
clinical outcome for DO-1 (p<0.0001); hazard ratio 5.9 (95% Cl 1.2-28.7) and
DO-7 (p<0.01). TP53 expression was also found to be associated with high
stage (3 and 4) (p=0.007). There was no relationship with any of the other
proteins studied, nor was immunostaining for any of these other proteins
related to clinical outcome. In 16 cases where primary tumour and bone
marrow was studied there were no significant difference in Ki-67, WAF-1 BCL-
2 or BAX or DO-1 expression between the 2 sites, however TP53 expression
detected by DO-7 was found to be lower in the bone marrow (p=0.044)
(median difference (MD) 4%). In the 32 bone marrow biopsies there was no
relationship between expression of any of the proteins studied and clinical
outcome. In the 16 tumours studied Pre-C and Post-C there was a significant
reduction in Ki-67 (p=0.001, MD 31%) and nuclear TP53 expression (DO-7,
p=0.05, MD 7.3%, DO-1, p=0.02, MD 6.7%) Post-C. In 22/26 tumours Post-C
there was evidence of differentiation towards ganglion cells. In 5-50% of these
differentiated cells cytoplasmic TP53 was detected with both TP53 antibodies.
Conclusions In neuroblastoma primary tumours nuclear TP53 accumulation is
associated with high stage and adverse clinical outcome. A larger study is
underway to determine if TP53 is an independent prognostic marker. There
was no association betweenTP53 or related protein expression in the bone
marrow and clinical outcome. Nuclear TP53 expression falls Post-C and
becomes detectable in the cytoplasm of differentiating neuroblastoma where it
may have a role in the induction of differentiation.
6.10 Onyx-015, an E1B deleted adenovirus, enhances
the cytotoxicity to cisplatin and radiation in the functional p53
human ovarian adenocarcinoma cell line A2780.
I Ganly*,R Brown.CRC Dept ofMedical Oncology,CRC Beatson Laboratories,
Glasgow G61 IBD, Scotland.
Adenoviral EIA increases cytotoxicity to DNA damaging agents such as
chemotherapy and radiotherapy by p53 dependent and independent pathways. An
EIB attenuated adenovirus,Onyx-015, has been reported to synergistically increase
sensitivity ofcells with nonfunctional p53 to cisplatin and 5FU (Heise et al;Nature
Medicine 1997; 3:639) AIMS: (I)To determine if an EIB deleted adenovirus,
Onyx-015, would increase cytotoxicity to cisplatin and radiation in the cell line
A2780 which has functional p53. (2) To determine if there was any relationship
between cytotoxicity and p53 expression and function. METHODS: (I) A2780
cells were infected with Onyx-015 at a MOI of 100pfu/cell and cell lysates made
over a time course of72hours. Expression ofp53, p21 and viral E40RF6 proteins
was determined by Western blotting. (2) Clonogenic survival assays were done at a
MOI of 1,10 and 100pfu/cell Onyx-015 alone and in combination with either
cisplatin ( 1, 5, 10 and 20pM) or radiation( 0.25, 0.5, 1 and 2Gy). Cells were
infected for 24hrs and 72hrs before being exposed to cisplatin or radiation.
RESULTS: (1) Cytotoxicity to cisplatin and radiation was enhanced by Onyx-015
infection. For instance, clonogenic survival with Onyx-015 alone at a MOI of
lOOpfI/cell was 0.18, radiation alone of 0.5Gy was 0.65, and Onyx-015 plus
radiation was 0.13. Thus clonogenic assays showed cytotoxicity was additive rather
than synergistic. (2) Onyx-015 infection produced a dramatic rise in expression of
p53 in A2780 which was sustained over 72hours. Expression of p21 was induced
for 24hours and then reduced to basal levels by 72hours despite high levels ofp53.
The reduction in p21 occurred when expression of adenoviral E40RF6 was
maximal. This suggested p53 transcriptional activity was downregulated by
E40RF6 possibly by complex formation to p53. (3) Cytotoxicity to cisplatin and
radiation after exposure toOnyx-015 for 24 hours and 72 hours were similar. This
suggested there was no correlation between cytotoxicity and Onyx-1O5 induced
effects on p53 transcriptional activity. CONCLUSION: Overall, cytotoxicity with
Onyx-O15 in combination with either cisplatin or radiation is better than each
agent alone. Therfore, EIB deleted adenoviruses may be useful adjuvants to
chemotherapy and radiation in tumours with functional p53 as well as in tumours
with nonfimctional p53.20 Oral Phesentatbons
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73 EXPRESSION OF DNA MISMATCH REPAIR
PROTEINS IN ACUTE LYMPHOBLASTIC LEUKAEMIA
AND NORMAL BONE MARROW. E C.Matheson*, A. G.Hall. LRF Molecular
Pharmacology Group, CRU, Medical School. Newcastle-Upon-Tyne, NE2 4HH.
Errors during normal DNA synthesis may produce mismatched
base pairs. 6-Mercaptopurine (6MP), given during continuing therapy
in acute lymphoblastic leukaemia (ALL), undergoes intracellular
activation to give cytotoxic thioguanine nucleotides which are then
incorporated into the DNA ofdividing cells in place ofguanine. Cell
death is thought to result from futile attempts at mismatch repair.
Previous work has shown that cell lines with a defect in this pathway
develop tolerance to incorporated 6-thioguanine bases. In order to
investigate the possible relevance of mismatch repair to the
chemosensitivty ofblasts to 6MP, relative to normal tissues, we have
measured the expression of the mismatch repair proteins hMLHI,
hMSH2, PMS2 and hMSH6 in blasts from children and adults with
ALL and in normal bone marrows, using Western blotting with
enhanced chemiluminescence detection and densitometry. Actin was
used as a loading control.
Fifty cases ofchildhood ALL, 22 cases ofadult ALL and 7 normal
marrows have been studied. Expression ofMSH2, and ofMLH1 in all
but three cases, was detectable in all the blasts studied. Noticeably,
expression of MLH1 was not detected in any ofthe normal marrow
samples. MSH2 was detected in 4 ofthe normal marrows. Expression
of PMS2 was not detected in 29 cases ofALL and, like MLHI. was
absent from each ofthe normal marrow samples. In contrast, MSH6
was detected in all ofthe normal marrows and all but 16 ofthe cases of
ALL. There was no difference in expression between adults and
children.
These results may help to explain the relative sensitivity of
leukaemic blasts to thiopurines at presentation as compared to normal
bone marrow. This work was supportedby the Leukaemia Research Fund
7.2 G-U4C CEVWAB AND ACUMEDRSMANCE
TO -my MIYLATlE SYNIMASE IN MORS Jaffrey R-G. I,
Mash S.', Prisd S.C.',Jogut P. G.2,Cassidy J.', McLeod iL'. 'Oncoloy Grow,
Departnust ofMedicine & Therapeutics, University ofAberdeen, AB25 2ZD, UK., Departnent of
Oncology, Queen's University ofBelfast, UK.
Drug resistance is a major obstacle to improving the utility ofcurrent
chemotherapy agents. Thynidylate synthase (TS) inhibitors are very commonly
used inthe treateent ofmany cancersincluding colon, breast, and head andneck.
We evaluated the role ofgenomic instability in three chemotherapy sessitive
huma carcinoma cell lines anddaughter cell lines displaying derived resistance to
Tomudex(MCF7-TDX, H630-ThX), or 5-fluorouracil (R1O-5FU). Genomic
instability between thepairedparentandresistantcells was de ed by directly
incorporating [a-2P dCTP into aPCR-amplified microsatellitereaction, the
products separated on a 6.5%polyacrylamide sequenc gel, followed by
radiography. Mirosatellitepinmems forregions throughoutthe genom were
used, including loci on ch nosoes lp36, 2p, 3p, Sq, 17pl3, and l8pl1.32. No
evidence ofgenomic instability (0/30 loci) was observedbetween MCF7 and its
resistant clone MCF7-TDX A highdegree ofloss ofheterozygosity, and allelic
instability was observed in H630 andRIO resistant cells. The results in H630 and
RIO suggest thatmicrosatellite instability is associatedwith chemothrapeutic
resistance. Theputative relationshipbetweengenosic instability andresistance to
TS inhibitors is currentlyunderinvestigatin As genomic instability is a common
finding in tumourtypes forwhich TS inhibitors are used, this may represent a
clinically important mechanism ofresistance.
7.4 CHEMOTHERAPY AND MUSCLEINVASIVE BLADDER CANCEL
ASSESSMENT OF P53 MAMUNO-REACTPVITY (IR) AS A PREDICTOR OF
RESPONSE. KN Qureshi-". T.RL Griffithsn. C Mus3. KLC Robinson3. RR Hal. J Laec' amd
D.E Nea12 'Cancer Reseach Unit. 1Depuunent of Surgm. University of Newcastle NE 4HH,
'Depatmene ofPahology. Northern CancerNetwork. Freeman HospitaL Newcastle UponTyne NE7 7DN
Studies of patients with muscle-invasive bladder cancer treated by radical
cystectomy have generally suggested that tumours with high p53 IR are more
likely to have a poor outcome. In contrast, a recent study (Cote et al, 1997
Nature 385 124) has suggested that this group is more chemosensitive.
We identified 83 patients with non-metastatic muscle-invasive bladder cancer
treated with cisplatin-based systemic chemodterapy. Of these patients, 31
were treated with chemotherapy only; the remainder had further adjuvant
treatment in the form of salvage cystectomy or radiodtrapy. Paraffin-
embedded sections ofbladder tumour obtained at transurethral resection prior
to chemotherapy were stained for p53 (1801 antibody) using a heat-based
antigen retrieval method.
Nuclear staining for p53 was demonstrated in 36/83 (43%) oftumours (range
of % p53 positivity: 0-91%). There was no significant difference in cancer-
specific survival for patients treated differently. Overall, p53 did not predict
complete response (CR), complete and partial response to chemotherapy, or
predict time to death from bladder cancer. However, in 48 patients in which
complete data was available treated with chemotherapy and subsequent
adjuvant therapy, >20%!. p53 staining was associated with improved survival
(P=0.009) with a 5 year survival of60!; for those with <20% p53 IR the 5
year survival was 21%. Multivariate analysis demonstrated that > 20/!. p53
staining (P=0.006) and CR (P=0.011) were independent predictors ofcancer-
specific survival in this group. Of the 48 patients, 17 patients were treated
with chemotherapy and subsequent salvage cystectomy. In this subgroup,
>20/o p53 staining was associated with improved survival (P=0.028). In
contrast p53 was not associated with survival in 27 patients treated with
chemotherapy and salvage radiotherapy.
P53 immuno-positivity did not predict response to systemic chemotherapy in
muscle-invasive bladder cancer. However, >20% p53 IR may identify a
subset ofpatients who benefit from subsequent salvage cystectomy following
chemotherapy.Oral Presentations 21
7.5 CHROMOSOMES 7 AND 17 AS PREDICTORS OF
DISEASE RECURRENCE AND PROGRESSION IN TRANSITIONAL CELL
CARCINOMA OF THE URINARY BLADDER.ADWatters I, SABallantyneI,
JJGoing2 KMGrigor3, TGCooke1& JMSBartlett .University Depts ofSurgeryI and
Pathology2, Glasgow Royal Infirmary, Glasgow, University Dept of Pathology3'
Edinburgh.
Transitional cell carcinoma ofthe urinary bladder is the fourth commonest cancer in
UK males. A particular characteristic of this disease is the high rate of recurrence
(80%), which carries a 10-20% risk of progression to muscle invasion following
presentation. This heterogeneity implies that a range ofgenetic lesions are involved.
Molecular markers are ofgreat interest as another tool fordiagnostic and therapeutic
strategies. As technologies improve, these are becoming more viable in clinical
settings.
FISH is reliable and reproducible and widely used to study numerical chromosomal
aberrations. The significance of chromosomes 7 and 17 copy number in recurrence
and progression was investigated in 128 sequential carcinomas from 52 patients with
complete follow-up (mean = 4.8 years). Using archival material and alpha satellite
probes, results were assessed quantitiatively, a proportion by 3 independent
observers. Mean inter observer variation was < 10% for either chromosome. No
abnormality was observed for chromosomes 7 and 17 in patients who did not recur
(n=20). 31% (10/32) ofpatients who recurred showed an increase in copy number
for either chromosome, in their primary tumours (p=0.0082). Of these 7/11 (55%)
with recurrent progressive disease demonstrated significant increases in either
chromosome in multiple tumours prior to muscle invasion (p=0.0198). This data
therefore presents a potential diagnostic molecular marker of recurrence and
progression in transitional cell carcinoma.
7.7
PROGNOSTIC SIGNIFICANCE OF STROMELYSIN 3 (ST3)
LEVELS INHUMAN BREAST CANCER AND DEMONSTRATION OF NOVEL
ST3 EXPRESSION IN METAPLASTIC BREAST CARCINOMA CELLS WHICH
HAVE UNDERGONE EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT),
A Ahmad'*, A Hanby2, EA Dublin2, RD Rubens2, DM Barnes2 and IR Hart',
'Richard Dimbleby Dept of Cancer Research/1CRF, St Thomas' Hospital, London
SEI 7EH, ICRF Clinical Oncology Unit. Guy's Hospital, London SEI 9RT.
The matrix mietalloproteinase ST3 has been implicated in breast
carcinoma progression firom its expression in the stromal fibroblasts adjacent to
invasive breast carcinoma cells. To assess the prognostic significance of ST3
expression, a mouse monoclonal antibody, raised against the ST3 haemopexin
domain, was used to immunostain pre-invasive (28 cases ofductal carcinoma in-situ)
and invasive (30 of each grade ofductal, 28 lobular and 14 cases of 'metaplastic'
carcinoma) breast cancers. In contrast to pre-invasive disease, where only 6/28 DCIS
cases expressed ST3, stromal fibroblasts in 72/91 cases (80%) of invasive ductal
carcinoma expressed ST3 (p<0.0001). Levels of ST3 expression in these invasive
cancers showed no correlation with tumour grade, axillary nodal status or oestrogen
receptor status. However, patients with invasive ductal carcinoma exhibiting
moderate or strong levels of fibroblastic ST3 expression (n=40) had significantly
shorter disease-free survival than those with negative or weak ST3 levels (n=50) (=
5.62, p=0.02). Univariate analysis was used to determine the prognostic significance
of ST3 levels relative to nodal status, histological grade, tumour size and age. ST3
expression levels were a stronger prognostic factor in predicting disease-free survival
than nodal status and ofsimilar prognostic value to tumour grade. Patient
subdivision according to nodal status, revealed ST3 level as a strong predictive factor
for relapse-free survival in the 53 patients with node postiive breast cancer (( 2=
7.0)1, p=0.0081). Multisariate analysis, including other previously identified
prognostic tactors. determined that, in node-positive patients, ST3 level was a strong.
independent prognostic parameter for disease-free survival (p=0.005).
Immunostaining 14 cases of the metaplastic carcinoma subgroup revealed,
for the first time, ST3 protein expression in spindle-shaped neoplastic cells. In-situ
hybridisation confirmed that these spindle-shaped cancer cells also expressed ST3
mRNA. Antibodies to vimentin and cytokeratin (CAM 5.2) established that many of
7.6
EXPRESSION OF CYCLIN DEPENDENT KINASE INHIBITORS IN
LARYNGEAL CANCER
*Jean-Pierre Jeannon, 'James V Soames, OJohn Lunec, *Janet A Wilson &
'Charles G Kelly. *Departments ofOtolaryngology, 'Oral Pathology,
'Oncology & "Cancer Research Unit, University ofNewcastle upon Tyne.
Introduction: The cyclim dependent kinase inhibitors control the cell cycle
and include p21 (WAFI) and p27 (KIPI) '. p27 expression is a reliable
prognostic indicator in breast and colo-rectal cancers where low levels are
associated with poorprognosis 2.
Aims: To determine if: (1) p27 is expressed in laryngeal cancer (2)
expression relates to prognosis.
Methods: A retrospective study on formalin-fixed paraffin embeddedtissue
randomly chosen. Specimens were immunostained with monoclonal
antibody to p27. Scoring was at high power magnification on random fields.
Positive, negative andnormal controls were employed. High positivity was
defined as >50% positive cells per field. Maximum follow-up was 9 years.
Results: 50 cases were included in the study, all ofwhich stained positive
to p27. Complete case notes were available on 39: 23 TI/T2 glottic, 5 T3/T4
glottic, 5 TI/T2 supraglottic & 6 T3/T4 supraglottic cancers. Low p27
expression was associated with poor survival outcome in early glottic cancer
(table 1).
TI / T2 Mean Survival
p27 Expression N (months) p=0.05 Mann-
Low 4 37 WhitneyU
High 19 68 Test
Summary: We have demonstrated p27 expression in laryngeal cancer for
the first time. Low levels ofp27 expression appear to be associated with
poor prognosis in early glottic cancer.
References: 1. Morgan D. The dynamics ofcyclin dependent kinase
structure. Current Opinion in Cell Biology. 1996 (8): 767-772. 2.Stegg P
&Abrams J, Cancer prognostics: Past, present and p27. Nature Medicine
1997 3: 152-154.
7.8 EVALUATION OF AN ENRICHMENTAPPROACH FOR
SELECTION OF PROGNOSTIC MARKERS IN NSCLC. Pritchard,
S.C.", Kerr, K.M.2, Lloret, C.', Nicholson, M.C.2, Cockburn, J.S2, Jeffrey, R.R.2, M'Leod, H' 'Dept
ofMedicine & Therapeutics, University ofAberdeen, Foresterhill, Aberdeen, UK, AB25 2ZD.
2Depts ofPath,Clinical Oncology& Surgery, Aberdeen Royal Infirmary, Aberdeen, UK, AB25 2ZD.
Lung cancer is the most common cause ofcancer death in the world, accounting for
nearly 800,000 deaths per year. In stage II Non Small Cell Lung Cancer up to 50% of
patients die within 3 years ofsurgery, therefore more accurate methods are required to
identify patients at risk from disease recurrence. Conventional methodologies for
identifying putative markers ofprognosis require large numbers ofpatients to test a
small number ofmarkers. We used an 'enrichment' approach to identify genes or
genomic regions associated with survival. Patients were selected for the extremes of
clinical outcome: 20 patients were alive 3 years post diagnosis and 20 patients had
died 2-12 months post diagnosis. Using microsatellite analysis and
immunohistochemistry we assessed multiple areas ofimportance for tumour biology
including cell proliferation, apoptosis, invasion and genetic instability. Expression of
MMP-1, MMP-2 ,TIMP-2, P53, BCL2 and PCNA were not associated with survival.
Our studies showed a high level ofmicrosatellite instability in stage II NSCLC. Loss
ofheterozygosity (LOH) at 3pl4, 3p2l, 3p25 and 17p were not associated with
survival. LOH at 9p22-23 was associated witil better survival and more extensive
evaluation ofthis locus is underway. This data suggests that the use ofan enrichment
approach can eliminate markers from time consuming and expensive larger studies
andprovide pilot data for definitive marker analysis.
the ST3-expressing tumour cells co-express fibroblastic and epithelialcell surface
markers, indicating that they have undergone adegree of EMT. These data indicate
that ST3 has prognostic importance in breast cancer and that the expression of ST3 in tumour cells may contribute to the increased metastatic capability seen in certain
metaplastic' breast carcinomas.22 Oral Presentations
7 E9 GLUTATHIONE S-TRANSFERASE THETA FAMILY
mRNA EXPRESSION IN HUMAN COLORECTAL CANCER. K-J.Palmer*.,
A.C.Gough., I.Srouji., H.Chave. and J.N.Primrose. University Department of
Surgery, Southampton General Hospital, Southampton, Hampshire, SO16 6YD.
The Glutathione S-Transferases (GSTs) are a superfamily of enzymes
which play an important role in the detoxification of carcinogens and the
metabolism of chemotherapeutic agents. There are four main subclasses: alpha,
mu, pi and theta. Many ofthese exhibit a high degree of intervariability in their
levels ofexpression, attributed in part to genetic polymorphisms. As the colon is
a major site for carcinogen exposure from the diet and environment, it is
important to deduce the expression of these enzymes and the influence of the
polymorphisms on colorectal cancer. In this study, we have examined the mRNA
expression pattern of the two members of the GST theta family, GSTT1 and
GSTT2 in 25 matched colorectal tumour/mucosa pairs.
Total cellular RNA was extracted from matched colorectal mucosa and
tumour pairs and subjected to reverse transcription (RT) using an oligo dT
primer. RT-PCR was performed using specific oligonucleotide primers to detect
GSTT1, GSTT2 and P-actin mRNA. The PCR products were analysed by non-
denaturing polyacrylamide gel electrophoresis and visualised by ethidium
bromide staining under ultraviolet transillumination. The specificity of the PCR
products were confirmed by sequencing.
GSTT1 mRNA was expressed in 80% (20/25) of mucosae and 88%
(22/25) of tumour samples and GSTT2 mRNA in 52% (13/25) of mucosae and
84% (21/25) of tumour samples. Increased levels of expression of GSTT2, but
not GSTT1, was observed in tumour samples (P=0.004 and P=0.1842
respectively; Wilcoxon Matched Pair Signed Ranked Test). The null GSTT1
genetic polymorphism was found in 12% (3/25) ofthe population studied which
were negative by RT-PCR.
In conclusion, this study suggests that both GSTT1 and GSTT2 mRNA
are expressed in normal colonic mucosa and tumour samples. GSTT2, but not
GSTT1 gene expression appears to be upregulated in colon cancer which may be
important in inherent resistance ofcolorectal tumours to chemotherapy.
8.1
CONTROL OF HEMATOPOIETIC STEM CELL
RENEWAL AND LINEAGE COMMITMENT BY THE
RETINOBLASTOMA TUMOR SUPPRESSOR GENE. K. Macleod' &
T. Jacks'. 'Dept. of Molecular and Cellular Pathology, University of Dundee,
Dundee DD1 9SY; 'The Center for Cancer Research, The Massachusetts Institute
ofTechnlogy, Cambridge, USA.
The retinoblastoma tumor suppressor gene encodes a critical cell cycle
regulator, pRb, involved in regulating the passage of cycling cells through the G1
phase of the cell cycle. pRb is also required for the establishment/maintenance of
cell cycle exit during the differentiation of certain cell types. In particular, loss of
Rb function in the developing mouse embryo has been shown to result in failed
differentiation in the nervous system, the ocular lens and in fetal liver
hematopoiesis.
We set out to investigate the role of Rb in controlling hematopoietic
differentiation. In particular we were interested in the role of Rb in regulating stem
cell entry into cycle and in determining the lineage commitment of hematopoietic
progenitors. We compared the ability of fetal liver tissue from wild-type and Rb
mutant embryos to repopulate lethally irradiated adult host mice. While Rb mutant
fetal liver can rescue short and medium term hematopoiesis, it failed to repopulate
transplanted mice on a long-term basis. These results suggested that the long term
repopulating stem cell in Rb mutant fetal liver is defective. Mice rescued with Rb
mutant fetal liver diedprematurely due to anemia manifest in a very low hematocrit
and the absence oferythroid progenitors in the bone marrow and spleen. However,
the bone marrow, spleen and liver of these mice was over-populated with mature
granulocytes, macrophages and megakaryocytes resulting in splenomegaly and an
enlarged liver. The cell cycle profile of putative stem cells and of myeloid
progenitors from the bone marrow of mice rescued with wild-type and Rb mutant
fetal liver was analysed by FACS. A reduced number of stem cells were detectable
in the bone marrow of mice rescued with Rb mutant fetal liver. Furthermore, an
increased proportion of these stem cells were in S or G2/M phases of the cell cycle
compared to stem cells from wild-type rescued bone marrow. These results suggest
that Rb mutant stem cells become depleted in the bone marrow of rescued mice due
to an aberrantly high rate of cell cycle entry. Furthermore, there is over-
commitment to certain myeloid lineages at the expense of erythroid progenitors,
which undergo apoptosis. Bone marrow from Rb mutant rescued mice was not
leukemogenic when transplanted into nude mice. In contrast, mice rescued with
fetal liver lacking the function of both the Rb and p53 tumor suppressor genes did
develop a transplantable leukemia.
7.10 INCREASED EXPRESSION OF CYTOCHROME P450
ISOFORMS IN MOUSE TUMOURS AND THEIR ROLE
IN THE ENHANCED ACTIVATION OF THE BIOREDUCTIVE DRUG,
A Q 4N. MM Murray*i, T Robsonl, R Gallagherl, LH Patterson2, DG Hirstl, SR
McKeownl. 'Radiation Science Group, School of Biomedical Sciences, University of Ulster,
Jordanstown, N. Ireland; 2Dept of Pharmaceutical Sciences, De Monfort University, Leister, UK.
The CYP superfamily of enzymes, in particular the CYP3A family, play
a central role in the metabolism of numerous anticancer drugs. Although CYPs are
commonly thought of as oxidases they also have well defined actions as reductases
under hypoxic conditions. Indeed, we have evidence that suggests that they are
involved in the metabolism of the novel bioreductive drug, AQ4N (1,4-bis-( [2-
(dimethylamino-N-oxide)ethyl]amino}5,8-dihydroxyanthracene-9,I0-dione).
Freshly excised tumour cells under hypoxia metabolise AQ4N extremely
efficiently (in vitro tI/2 26 min). However, wel have shown that if the tumour
cells were cultured under normal conditions for 24h before exposure to AQ4N under
hypoxia, no DNA damage was observed although the drug was taken up by the
cells; alterations in the expression of CYP 3A4 may be responsible. To study
AQ4N (and other CYP-sensitive drugs) in vitro, and to increase their metabolism
in vivo we decided to overexpress a range of CYP isoforms in the RIF-1 tumour
cell line.
We have transfectanted the RIF-1 cell line with the LNCX retroviral
vector containing the following CYP isoforms CYPIAl. CYPlA2, CYP2C10,
CYP2E1 and CYP3A4. Transfectants were isolated by growth in selective medium
(G418). The transfectants were relatively stable (>50%) in vitro and in vivo.
Results from growth curves indicate that in vitro doubling times for all
transfectants were similar in selective and nonselective medium. Furthermore,
transfection did not have an appreciable effect on growth rate as compared to the
parental cell line.
In vitro metabolism studies were used to measure the ability of the
transfectants to metabolise AQ4N. Incubations consisted of S9 protein (5 mg/ml),
AQ4N (5OiM), NADPH (15mM) in phosphate buffer at pH7.4 under nitrogen.
The reaction was stopped at various times by the addition oflow pH mobile phase.
Residual AQ4N was quantified by reverse phase isocratic HPLC using a C8
column with a mobile phase of 80% 0.5M ammonium formate/20% acetonitrile
(pH 4.2). All transfectants, except CYP2E1, metabolised AQ4N to a greater extent
than the parental line. The drug was mosteffectively metabolised by the CYP3A4
and 2C10 transfectants, with in vitro halflifes of41 and 43 min respectively.
References:
1 Hejmadi, M.V. et al. Br. J. Cancer, 73, 499.
8.2 ACTIVATED MUTANTS OF THE HUMAN GM-CSF RECEPTOR
°, SUBUNIT CAUSE MYELOPROLIFERATIVE DISORDERS
AND LEUKAEMIA IN MICE. M.P.McCormack* and T.J.Gonda,
Department of Human Immunology, Hanson Centre for Cancer Research, Frome
Road, Adelaide 5000, Australia.
To date several activating mutations have been discovered in the common
signal-transducing subunit (hoc) of the receptors for human granulocyte-
macrophage colony stimulating factor (GM-CSF), interleukin (IL)-3 and IL-5, which
enable it to signal in the absence of ligand. Two of these mutations, V449E and
1374N, result in single amino acid substitutions in the transmembrane and
extracellular domains of hoc, respectively'. A third, FIA, results in a 37 amino acid
duplication in the extracellular domain We have shown previously that, when
expressed in primary murine haemopoietic cells, the extracellular hoic mutants could
confer factor independence on cells of the neutrophil and macrophage lineages only.
However, the transmembrane mutant, V449E, could confer factor-independence on
all cell types of the myeloid and erythroid compartments.
In order to study the effects of hoic mutants in vivo, we have expressed all three
mutants in the haemopoietic system of mice by the technique of bone marrow
reconstitution. The extracellular ho~c mutants FIA and 1374N induced a chronic
myeloproliferative disorder marked by elevated levels of neutrophils, red blood cells
and platelets in the blood. In contrast, the transmembrane hoc mutant V449E
induced an acute disorder of blast cell accumulation in the blood, reminiscent of
leukemias such as AML. Hence whilst activated hBc mutants are capable of inducing
haemopoietic disorders, the type of disorder induced depends on the location of the
activating mutation.
1. Jenkins, B.J., D'Andrea, R. and Gonda,T.J. (1995) EMBOJ. 14: 4276-4287.
2. D'Andrea R, Rayner J, Moretti P, Lopez A, Goodall GJ, Gonda TJ, Vadas MA.
(1994) Blood83: 2802-2808.
3. McCormack, M.P. and Gonda, T.J. (1997) Blood90: 1471-1481.OralPresentations 23
DIAGNOSIS OF NON-HODGKINS LYMPHOMA BY FINE 8.3 NEEDLE ASPIRATE BIOPSY. AN ANALYSIS OF THE
RELATIVE CONTRIBUTIONS OFCYTOMORPHOLOGY,
IMMTUNOPHENOTYPE AND GENE REARRANGEMENT STUDIES. NJ Mulligan*. M Zucca.
B Burke, Gilbride K, C O'Hara. Mallory Institute of Pathology, Boston Medical Caeter, 784 Mass
ave., Boston, MA 02118, USA.
The role of fine needle aspirate biopsy in the diagnosis of lymphoma has
traditionally been restricted to staging or detection of relapse. We attempted to
reach a rapid and accurate initial diagnosis on aspirated material from lymph
nodes using morphology, surface marker detection by flow cytometry and PCR
analysis ofimmunoglobulin gene rearrangements. The relative contributions of
each of these diagnostic modalities was analyzed and compared with the final
histological diagnoses. The cases consisted of 10 cases of non-Hodgkin's
lymphoma, 3 cases of Hodgkin's disease and 5 cases of reactive lymphadenitis.
The sensitivities of morphology, flow cytometry and PCR for the diagnosis of
non-Hodgkin's lymphoma were found to be 80%, 89% and 70% respectively.
The corresponding specificities were 71%, 75% and 80% respectively. When
we applied criteria which required concordance between at least two of the
three modalities to reach a diagnosis, the sensitivity and specificity for the
diagnosis of NHL increased to 90% and 86% respectively. The lymphomas
were classified according to the Working Formulation and concordance was
found in 78% of the cases between the initial cytological and the final
histological diagnosis.
Conclusions: Preliminary findings from this ongoing study demonstrate that
fine needle aspirate biopsy is a useful tool in the initial diagnosis of non-
Hodgkin's lymphoma. Analysis of a combination of morphology,
immunophenotype and gene rearrangement studies appears to improve
diagnostic accuracy when compared with any of these modalities alone. The
impact of molecular marker studies (PCR detection of tL: 14 and t14:18) on
the accuracy ofclassification will be assessed as additional cases are accrued.
8.5 THIOPURINEMETHYLTRANSFERASEGENOTYPEAND
PHENOTYPE IN NORMAL SUBJECTS AND PATIENTS
WITH ACUTE LEUKAEMIA S. Coulthard,* C. Howell, J. Robson and A.G.Hall,
LRF Molecular Pharmacology Group, CRU, Medical School, Newcastle, NE2 4HH
Acute lymphoblastic leukaemia (ALL) is the most common malignancy
ofchildhood. Although current treatment results in long term survival in over
70% of cases there is evidence that as many as 50% could have been cured
using a less complex regime with a lower incidence of long term side effects.
In previous studies it has been found that thiopurines given as part of
continuing therapy are key agents in preventing relapse. However optimal
administration during continuing therapy is often not achieved. Variations in
the level of thiopurine methyltransferase (TPMT) activity appear to be a
major determinant of the extent of thiopurine metabolism. This is partially
due to the presence of mutated TPMT genes in approximately 1 1% of the
population. There have been seven mutation sites reported to date which
result in reduced TPMT activity, (Ottemess et al 1997 Clin. Pharmacol. Ther.
62 60). We have screened 97 normals for mutations at the three best
characterised loci, position 238, 460 and 719 (Krynestski, et al 1996
Pharmacogenetics6 279, Szumlanski et al 1996 DNA and Cell Biology 15
17, Tai et al 1996 Am J. Hum. Genet. 58 694). The normal sequence is
designated *1, mutations at both 460 and 719*3A, mutated at 460 alone *3B
and mutated at 719 alone *3C. In all we have identified 89 homozygous for
the wild type gene (TPMT*I/*1) and 8 heterozygous (7 TPMT *l/*3A and
I TPMT *I/*3C). The mean enzyme activity level was significantly higher
in red blood cells in the group ofhomozygotes (I9.lU/l0I erythrocytes) than
in heterozygotes (9. 1 U/I
O erythrocytes, p<0.000I).
In a separate study of60 cases ofALL and AML in which lymphoblast,
rather than erythrocyte, TPMT activity was compared with genotype we have
shown that the level ofactivity in homozygotes was significantly lower than
in heterozygotes (0.15 v 0.32 nU/mg protein, p<0.008). The level of
homozygous TPMT activity in AML patients was compared to that in ALL
patients and was found to besignificantly higher in the AML group
(0.37nU/mg protein v 0.27nU/mg protein, p<O.02). These results report blast
activity and genotype comparisons for the first time and suggest that both
genotype and transcriptional factors influence TPMT activity in leukaemic
cells. This work was supported by the Leukaemia Research Fund.
8.4 P53 MEDIATES BREAKDOWN OF THE ANTI-
APOPTOTIC PROTEIN BCR-ABL IN K562 LEUKAEMIA CELLS.
A. DiBACCO AND T.G. COTTER, Dept. of Biochemistry,
University College Cork, Ireland.
Previous work from this laboratory has demonstrated that Bcr-Abl
which is expressed in the CMIL cell line K562 is a potent inhibitor of
apoptosis when those cells are exposed to a variety of cytotoxic
agents. In the present set of experiments we demonstrated that when
K562 cells, which do not contain a functioning p53 protein molecule,
were transfected with a temperature sensitive construct ofp53 (ts-p53)
they became sensitive to the induction of apoptosis by doxorubucin at
the permissive temperature. Normally, untransfected cells are quite
resistant to the effects ofdoxorubucin and we were interested to know
how p53 reversed this resistance. Using western blotting we were
able to demonstrate that at the permissive temperature p53 mediated a
breakdown of Bcr-Abl into two fragments. This piece of data
suggested that p53 can induce the proteolytic cleavage of Bcr-Abl by
an ICE-like protease. To determine if this was being mediated
through activation of caspases and perhaps as a consequence of
apoptosis rather than an early event we will use zVAD to inhibit both
caspases and apoptosis. These results will indicate if p53 mediated
cleavage ofBcr-abl is an ehrly event in the apoptosis pathway and if it
precedes caspase activation. Using immunoprecipitation we were able
to demonstrate a direct interaction between p53 and Bcr-abl. The
significance ofthis last piece of information is still unclear.
This work was supported by Fobairt and The Irish Cancer Society.
KEY WORDS: p53, Bcr-Abl, apoptosis
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Mc ElwaineS*,Gowing Hl,Lawler Ml,Hollywood DH2,Cotter TC3,McCann SR'
Depts Haematolog,Oncolgy2, TCD, Dept Blochemlstry3,UCC Ireland.
In Chronic Myeloid Leukaemia (CML), the generation of a leukaemia specific RNA
(bcr-abl) results in a leukaemia specific protein (p210) which confers an anti-
apoptotic phenotype on CML cells. The expression of this chimeric gene is central
to the pathogenesis and progression of thisleukaemia. Thisleukaemia specific RNA
provides an attractive target for antisense studies. However RNA secondary
structure may limit this approach and sequence dependent rather than sequence
specific effects have been observed. In an effort to overcome these potential
problems, we have chosen to downregulate bcr-abl with the use of a sequence
specific antisense oligodeoxynucleotide (ODN) directed against the translational
start site of the BCR gene as we feel this may lead to a more effective suppression
of bcr-abl expression. The nuclease resistance of two backbone chemistries
(phosphodiester and phosphorthioate) has also been compared invitro. ODNs with
the phosphodiester chemistry were rapidly degraded in the presence of FCS,
whereas the phosphorothioates exhibited minimal degradation at the 3' end of the
ODN; however this was not significantly increased over the course of the incubation
period and intact 18mer was present at 72 hours. The presence of CML cells did not
increase the degradation of the phosphorthioate ODNs when compared to a cell free
control. Invitro studies in CML cell lines (K562,LAMA 84, KYO1, BV 173) have
indicated that phosphorothioate ODNs complimentary to the start site can enter the
cell successfully (as judged by fluorescent microscopy and FACS analysis of 6-
FAM labelled ODNs), are stable in CML cells for> 72 hours and can bind to their
target sequence. The uptake of these fluorescently labelled ODNs can be improved
with permeabilising agents such as saponin as observed in K562 cells by FACScan
analysis, also the potential for using cationic lipids may facilitate the uptake of
ODNs with minimal toxicity. We are also examining the disribution and significance
of the BCR protein expression in normal cells. Normal BCR protein has been
detected in a number of haemopoietic lineages as yet a role forBCR has to be fully
elucidated. Initial data generated from a long term cobblestone area forming cell
assay (CAFC) indicates that incubating normal bone marrowMNC with a dose of 0-
10mM antisense and nonsense ODNs for 24 hours prior to plating does not affect
there ability to proliferate and form cobblestone forming areas, thus supporting this
approach as a potential purging strategy. This observation and the effect of
antisense on CML cell lines is currently being investigated in order to understand
the effect of downregulating bcr-abl on the phenotype of the CML cell.24 Oral Presentations
8.7 ABSENCE OF HHV8/ KSHV DNA IN PERIPHERAL
BLOOD AND BONE MARROW HARVESTS FROM
PATIENTS WITH MULTIPLE MYELOMA. N.Gardiner*', W. Livingstone',
P.Simmonds2, M.Lawler', S.R.McCann', P.V. Browne'.'Dept Haematology, St
James Hospital, Dublin &2Dept.Medical Microbiology, Edinburgh Medical School.
Human herpesvirus 8 (HHV-8), also known as Kaposi's Sarcoma
related herpesvirus (KSHV), has been implicated in Kaposi's sarcoma,
Castleman's disease and primary effusion lymphomas (PEL). Rettig et
d have recently demonstrated the presence ofHHV-8in bone marrow
biopsies andcultured stromal cellsfrom patientswith multiple
myeloma (MM).They propose that HHV-8may influence the switch
from MGUS to myeloma through the secretion ofviral IL-6from
infected bone marrow dendritic cells. Autologous bone marrow (BM)
and more recently mobilised peripheral blood stem cells (PBSC) are
routinely used to support high dose chemotherapy in MM. It is
possible thatthese harvests contain HHV-8. We therefore examined
the leukapheresis and bone marrow harvestsfrom 9MM patientsfor
the presence ofHHV-8 DNA using a sensitive nested PCR assay. BM
wascollected in steady state haemopoiesis and PBSC were collected
aftermobilisation with cyclophosphamide + G-CSF. DNA was
extracted from frozen samples of20leukapheresis products and 7 bone
marrow harvests. The nested PCR assay (2 x 30cycles) yields a
second round PCR product of423 bp with a sensitivity of 10- 10
using control DNA from a patient with Kaposi's sarcoma. Nested PCR
forHHV8-8 DNA was negative in 20/ 20 PBSC products and 7/7
autologous BM harvests from9MM patients.The integrity ofthe
extracted DNA was confirmed using PCRprimersforthe Prothrombin
gene (507bp). In conclusion, using a highly sensitive nested PCR
assay, no HHV-8 DNA was detected in PBSC and BM products for
clinical use.
8.8 INVESTIGATION OF THE MOLECULAR DEFECT
CAUSING MONOCYTE ESTERASE DEFICIENCY.
B.R.Coff', P.C.Winter2, G.M.Markey' & T.C.Morris'. Haematology Dept.,
Belfast City Hospital, Belfast &2Royal VictoriaHospital, Belfast. N. Ireland.
Subjects with familial monocyte specific esterase deficiency have a relative risk of
6.6 (confidence limits 1.6. 28.3) for developing non-Hodgkins lymphoma (Markey
et al J. Leukocyte Biology Supplement 1995 A147). Extracts from their peripheral
blood monocytes do not show the series of active isoenzymnes demonstrable in
monocytes from esterase positive subjects using isoelectric focusing on
polyacrylamide gels and non-specific esterase staining.
Monocyte carboxylesterase is specific to cells of monocyte/macrophage lineage.
The sequence ofthe gene for monocyte specific esterase has been established using
a cDNA cloned from the monocytic cell line U-937 by Zschunke et al (Blood 1991
78(2) 506).
In our study, primers to this sequence were designed and used to perfonu RT-PCR
on RNA extracted from peripheral blood monocytes purified by ficoll
centrifugation and miniMACS (Miltenyi Biotech) enrichment - the latter being an
immunomagnetic (CD14-labelled magnetic microbeads) procedure.
The 1623bp RT-PCR product obtained from purified esterase positive inonocytes
was sequenced and the sequence conformed to that ofHMSE I.
To date the RT-PCR products from three esterase negative subjects have been
sequenced and the active site and transmiembrane regions of the gene have shown
no abnonnalities. However. a consistent,Pro-Leu change in the intervening region
has been demonstrated in one ofthe MED subjects.
This study has shown that RNA is being transcribed from the HMSE I gene in
monocyte esterase deficiency providing the first step in elucidating the molecular
mechanism ofMED.
1. Rettig M. et al, Science: 276; 1851-1854, (1997).
8.9 SOMATOSTATIN RECEPTOR EXPRESSION IN LYPHOMA
OF MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT).
M.Radereri, J. Valencak', A. Kurtaran2, J. Drach', T. Pangerl2, M- Hejna', F. Pfeffel3,
A. Chott4 and 1. Virgolini2. Dept. Of Internal Med 11 and IV3, Nuclear Medicine2 and
Pathology3, University ofVienna, Wahringer Guertel 18-20, A-1090 Vienna
Extranodal lymphoma ofthe MALT- type is a distinct pathologic entity with a usually
indolent clinical course, which has been classified as marginal zone lymphoma
according to the REAL-classification. The majority of cases arise in the stomach and
are thought to be related to the presence of Helicobacter pylori, but also extragastric
locations are frequently encountered. While the optimal treatment of such patients
remains a matter of debate at the moment, there is widespread consensus that exact
staging including endosonography, CT-scanning, endoscopy and bone marrow biopsy
is mandatory. We report the results of a study evaluating the role of somatostatin
receptor (SSTR) imgaging using ii.In-DTPA-D-Phe I -octreotide ("'In-OCT) in 20
patients with MALT lymphoma, which displays a high affinity to SSTR-subtypes 2
and 5. In addition, we have investigated the SSTR-subtype expression in 4 human
MALT-lymphoma specimens (2 gastric and 2 extragastric). All patients included in
the study had histologically verified MALT-lymphoma: 6 had low-grade extragastric
manifestations ( llymphoma of the lung, 2 conjunctival lymphomas, I breast and 2
cases with supraclavicular lesions), 4 had stage I and 2 had stage 11 disease. 14
patients presented with gastric lymphoma (8 high-grade and 6 low-grade), 5 had stage
11 and 9 stage I tumours. All patients were injected "In-OCT before initiation of
therapy, and results of gamma camera imaging were compared to conventional
imaging including CT and endosonography. 19 patients were considered evaluable, I
patient with gastric lymphoma was excluded due to the additional presence of CLL.
All 6 patients with extragastric lymphoma had positive scans, while only I patient
with gastric lymphoma had slight focal tracer uptake in the epigastric area, which was
rated as unspecific. The remaining 12 patients had negative scans irrespective of low-
or high-grade histology. In vitro results also revealed a different pattern of SSTR-
subtype expression in extragastric and gastric MALT-lymphomas. These results
indicate that extragastric MALT-lymphomas can be readily visualized by SSTR-
imaging using "'In-OCT and might be potential targets for therapy with SST-
analogues. In contrast, gastric MALT-lymphomas do not appear to express relevant
amounts of respective SSTR. Our findings suggest a difference between extragastric
and gastric MALT-lymphomas on the cellular level despite a well established
morphologic and immunohistochemical uniformity.
8.10 A FLOW CYTOMETRIC ANALYSIS OF CYTOKINE EXPRESSION
IN PERIPHERAL BLOOD MONONUCLEAR CELLS FROM
COLORECTAL CANCER PATIENTS. K.M. Gaskell, J.Greenman and J.R.T.. Monson.
University of Hull Academic Surgical Unit, Castle Hill Hospital, Cottingham, East Yorks.,
HUI6 5JQ.
INTRODUCTION: It has been suggested that patients with malignant disease may exhibit
immunosuppression. Changes in cytokine responses could represent an important aspect of
immunosuppression in these patients. Flow cytometry protocols have recently been devised
which allow the analysis of intracellular antigens from specific cell populations within a
heterogeneous mix. This technique is quick and provides a quantitative assessment of cells
expressing a specific antigen ofinterest via measurement offluorescence intensity.
AIM: To compare levels of cytokine expression in peripheral blood mononuclear cells
(PBMC) from colorectal cancer patients and healthy controls, using flow cytometry.
METHODS: PBMC were isolated from 7 colorectal cancer patients and II healthy control
subjects. Each sample was divided into two parts. One part remainded untreated while the
other part was stimulated with phorbol 2-myristate 13-acetate and ionomycin for 2 hours in
the presence of monensin. Cells were fixed with paraformaldehyde, permeabilised with
saponin and labelled with specific fluorescent directly-conjugated anti-cytokine antibodies.
Cytokine-producing cells were analysed on a FACSCalibur flow cytometer (Becton
Dickinson). Gating on forward scatter and side scatter was carried out to define the
lymphocyte and monocyte populations. Markers were set on fluorescence histograms so that
only 3-5% of unstimulated cells were positive. The number of stimulated lymphocytes and
monocytes which fell within this positive region was then recorded. Medians and interquartile
ranges were calculated for the percentage of stimulated lymphocytes and monocytes in each
condition. The data for each cytokine was analysed using a Mann-Whitney U test (two-
tailed).
RESULTS: Statistical analysis demonstrated a highly significant (p<0.01) increase in the
number of cells producing TNF-a in colorectal cancer patients. The data also indicated a
trend towards an increase in cells producing IFN-y, IL-12 andTGF-0 in cancer patients, and a
decrease in cells producing IL-10, but these differences did not reach statistical significance.
Numbers ofcells producing IL-2 were only minimally increased in tumour patients.
DISCUSSION: The data displays clear trends in which the numbers ofcells producing TNF-
a, IFN-y and IL-12 are elevated in patients with colorectal cancer, as compared with healthy
controls. In the case of TNF-a the elevation was found to be highly significant. These 3
cytokines are known to drive aTHI type ofimmune response in which cell-mediated cytotoxic
reactions are promoted. For the group ofcancer patients tested therefore it appears that a THI -
like response is in operation. Furthermore, numbers ofcells producing IL-I0 were found to be
decreased in colorectal cancer patients as compared with healthy controls. This also
represents a favourable anti-tumour response since IL-10 is inhibitory to THI-like responses.
Further studies investigating larger numbers of cancer patients are required to confirm the
significance ofthese results.
CONCLUSION: Present findings suggest that inappropriate cytokine expression may not be a
major factor in the ineffectiveness of the immune response against colorectal cancer. We
hypothesize that failure of an effector function downstream of cytokine production is
responsible for the inability to control the tumour.